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Abstract 
Corticotropin-releasing hormone (CRH) is the master regulator of stress 
responses mediated by the hypothalamic-pituitary-adrenal (HPA) axis in mammals. 
CRH and CRH-related ligands, termed urocortins (UCNs), along with their receptors, 
CRHR1 and CRHR2, are expressed both centrally and peripherally. Evidence has 
implicated the CRH family of peptides in mechanisms regulating energy balance in the 
animal. Interestingly, Fyn kinase, a member of the Src kinase family, is also involved in 
homeostasis regulation. Fyn knockout animals display reduced adiposity partly due to 
increased energy expenditure and lipid utilization in white adipose tissues. Fyn kinase 
expression is down-regulated by glucocorticoids, suggesting that HPA axis might 
regulate Fyn, thereby implying a possible interaction with CRH. 
I sought to determine a possible crosstalk between CRH and Fyn kinase. Using a 
mouse model with total Crh deficiency (Crh KO mouse) and applying various metabolic 
challenges, such as cold exposure and induction of lipolysis processes, Fyn kinase 
expression was studied in tissues harvested from age-matched WT and Crh KO mice. I 
uncovered a novel positive correlation between CRH and Fyn kinase that was unmasked 
upon normalization of the Crh KO blood glucocorticoid. Activation of lipolysis 
pathways did not affect Fyn kinase expression, but unraveled differences between the 
two genotypes, both in vivo and in vitro. 
CRH plays an important role in activating thermogenesis of brown adipose 
tissue and therefore I sought to determine whether Fyn kinase had similar actions. A 
novel role for Fyn kinase activity in controlling brown adipogenesis was reported with 
the use of the brown preadipocyte line, T37i. Additionally, treatment of brown 
adipocytes with the Fyn kinase activity inhibitor, SU6656, provided evidence of an 
interaction between Fyn and Akt, whereas ERK1/2 remained unaffected. 
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Chapter 1 
Introduction 
1.1 Adipose tissue 
Adipose tissue evolved primarily to store energy in times of plenty and to 
provide fuel when sources become insufficient. Nowadays, it is acknowledged as the 
body‟s largest endocrine organ and it secretes hormones (adipokines), lipids, cytokines 
and other factors (Gesta et al., 2007; Nawrocki and Scherer, 2004; Spiegelman and Flier, 
2001). This dynamic tissue is able to respond to homeostatic and external cues and play 
central role in controlling appetite, glucose homeostasis, insulin sensitivity, aging, 
fertility, fecundity and body temperature (Berry et al., 2013). 
Adipose tissue is composed of adipose stem cells, adipocytes, mural, endothelial 
and neuronal cells (Riordan et al., 2009; Schipper et al., 2012). Various discrete depots 
have been described: inguinal, interscapular, perigonadal, retroperitoneal and mesenteric 
depots (Berry et al., 2013). In mammals, two main classes of adipose tissue exist, 
namely the white adipose tissue (WAT) and the brown adipose tissue (BAT), which are 
histologically and molecularly distinct and functionally distinguishable. 
Developmentally, white and brown fat cells derive from a common multipotent 
precursor in the somites, which also gives rise to skeletal myocytes, dorsal dermis 
(Kajimura et al., 2015). Before the adipogenic commitment of this precursor, cells 
positive in Pax7 (paired box protein 7), En1 (engrailed-1), Myf-5 (myogenin factor-5) 
and Ebf2 (early B cell factor-2) give rise to brown adipocytes (Wang et al., 2014). Ebf2 
and Bmp7 (bone morphogenic protein 7) control brown adipocyte differentiation by 
regulating the expression of Prdm16 (PRD1-BF-1-RIZ1 homologous domain-containing 
protein 16), C/EBP-β (CCAAT/enhancer-binding protein β), ZFP516 (zing finger 
protein 516), PPARγ (peroxisome proliferator-activated receptor γ) and PPARα 
2 
(peroxisome proliferator-activated receptor α) (Kajimura et al., 2015). White 
preadipocytes originate from Pax7-negative and Myf-5-negative precursors (Wu et al., 
2013) and PPARγ and TLE3 (transducin-like enhancer protein 3) are essential for their 
differentiation (Kajimura et al., 2015). 
1.1.1 White adipose tissues (WAT) 
WAT is designed for energy storage and is classically divided into subcutaneous 
and visceral depots. Histologically, subcutaneous fat is heterogeneous and contains 
mature unilocular adipocytes intercalated with small multilocular adipocytes, whereas 
visceral fat is more uniform and appears to consist primarily of large unilocular 
adipocytes (Tchernof et al., 2006; Tchkonia et al., 2007). These differences are 
physiologically significant as the expansion of subcutaneous fat may protect against 
from the deleterious effects of type 2 diabetes and glucose intolerance (Snijder et al., 
2003a; Snijder et al., 2003b), whereas, visceral depots expansion can associate with 
metabolic complications and increases the risk of diabetes, hyperinsulinemia and 
cardiovascular diseases (Grauer et al., 1984). This discrimination between the “good fat” 
and “bad fat” has its roots to the distinct histology of the two depots. More specifically, 
the large numbers of small multilocular adipocytes that reside in the subcutaneous fat 
have been shown to be protective against metabolic dysfunctions (Salans et al., 1973; 
Weyer et al., 2000). The increased interstitial tissue found in the subcutaneous depots as 
well as the increased rates of adipose turnover (Bjorntorp et al., 1971; Salans et al., 
1973), which constantly provides a pool of new and younger adipocytes, further enhance 
the “good profile” of the subcutaneous fat. Further, the anatomical localization of the fat 
pads is considered to be key aspect in the protection against hyperinsulinemia and 
glucose tolerance. In particular, the visceral fat is drained by the portal vein, which in 
case of nutritional imbalance, such as diet-induced obesity, provide additional fatty acids 
to the liver and this can cause hepatic insulin resistance (Bjorntorp, 1991; Despres et al., 
1995; Randle, 1998); whereas the close proximity of subcutaneous fat with the insulin-
3 
sensitive muscle mass at the gluteal region, promotes the beneficial effects of this 
adipose depot (Snijder et al., 2003a; Virtue and Vidal-Puig, 2008). 
Dietary non-esterified fatty acids (NEFAs) are esterified to the chemically inert 
triacylglycerol (TG) and finally stored in cytosolic lipid droplets (Lass et al., 2011). The 
increased energy demand, for example after fasting or exercise, mobilizes the energy 
reserves of WAT. This hydrolysis of TG is termed lipolysis and results in production of 
free fatty acids (FFAs) and glycerol. FFAs enter the circulation to be further catabolized 
by non-adipose tissues, such as skeletal muscles, via the β-oxidation pathway. Glycerol 
is taken up by the liver to provide substrates either for the glycolysis or the 
gluconeogenesis pathways. 
Lipolysis is driven mainly by three enzymes: adipose triglyceride lipase 
(ATGL), hormone-sensitive lipase (HSL) and monoglyceride lipase (MGL) (Lass et al., 
2011). ATGL resides on lipid droplets and gains full hydrolytic activity upon binding 
with its co-activator, comparative gene identification-58 (CGI-58) (Lass et al., 2006). 
CGI-58, also termed α/β hydrolase domain-containing protein-5 (ABHD5), strongly 
interacts with perilipin (see below), thus reducing interaction with ATGL (Granneman et 
al., 2007). ATGL hydrolyzes triglycerides to diglycerides and free fatty acids (FFAs) 
(Zimmermann et al., 2004). The hydrolysis of diglycerides to monoglycerides and FFAs 
is catalyzed by HSL (Haemmerle et al., 2002; Osuga et al., 2000), and the final step of 
lipolysis is catalyzed by MGL, which releases glycerol and FFAs (Karlsson et al., 1997). 
The phosphorylated forms of HSL and MGL translocate to lipid droplets to coordinately 
hydrolyze stored lipids. 
One of the most important activators of lipolysis are catecholamines, which bind 
to β-adrenergic receptors (β-AR) on plasma membranes of adipocytes (Cannon and 
Nedergaard, 2004). Coupling of the receptor to Gs proteins activates adenylyl cyclase 
and the intracellular signal is transmitted via cyclic AMP (cAMP) (Connolly et al., 1986; 
4 
Scarpace and Matheny, 1996). Subsequent activation of protein kinase A (PKA) leads to 
a series of phosphorylation events, which include activation of lipases and deactivation 
of perilipin (Figure 1.1). Perilipin is the protein that normally localizes around the 
triglyceride droplets within the cell (Blanchette-Mackie et al., 1995), thus protecting 
them against ATGL and HSL activity (Martinez-Botas et al., 2000). Modification of 
ATGL is not PKA-dependent (Schweiger et al., 2006; Zechner et al., 2012; 
Zimmermann et al., 2004). Activated PKA phosphorylates perilipin (Chaudhry and 
Granneman, 1999), which changes conformation and binds to phosphorylated HSL 
(Miyoshi et al., 2007; Shen et al., 2009; Wang et al., 2009). Lastly, HSL translocates to 
these sites of action (Egan et al., 1992; Londos et al., 1995). 
 
Figure 1.1: The lipolysis process. Under basal conditions, the lipid droplet is 
surrounded by perilipin molecules, which prevent lipolysis from both ATGL, because it 
strongly binds the ATGL co-activator, CGI-58, and HSL, because it has no access to 
lipid droplets. ATGL, which normally resides on lipid droplet surface, catalyzes (low 
activity denoted by the doted arrow) the first step of lipolysis: TG to DG and FFAs. 
Under stimulated conditions, catecholamines bind to β-AR and cAMP and PKA are 
activated. PKA, in turn, phosphorylates and deactivates perilipin, which changes 
conformation and binds to phosphorylated HSL, thus allowing HSL to translocate to the 
lipid droplets, where it gains full hydrolytic capacity and hydrolyzes DG to MG and 
FFAs. Upon perilipin phosphorylation, CGI-58 binds to ATGL, which has full 
hydrolyzing activity and catalyzes the first step of lipolysis (arrow). HSL = hormone-
sensitive lipase, ATGL = adipose triglyceride lipase, TG = triglyceride, DG = 
diglyceride, FFAs = free fatty acids, MG = monoglyceride, CGI-58 = comparative gene 
identification-58, β-AR = β-adrenergic receptor, cAMP = cyclic AMP, PKA = protein 
kinase A, P = phosphoryl group. 
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The product of lipolysis, FFA, are activated to acyl-CoA (Coenzyme A) by acyl-
CoA synthase, turned into acylcarnitine by carnitine acyltransferase I (CPT1) on the 
outer mitochondrial membrane, shuttled inside the mitochondria by carnitine-
acylcarnitine translocase and converted to acyl-CoA by carnitine acyltransferase II 
(CPT2) on the inner mitochondrial membrane. The ensuing β-oxidation of FFA (acyl-
CoA) produces acetyl-CoA, which enters the citric acid (or Krebs) cycle, leading to the 
formation of the reduced electron carriers, FADH and NADH, which are then oxidized 
by the electron transport chain (respiratory chain), ultimately through oxygen 
consumption. This results in a pumping out of protons from the mitochondrial matrix 
and the formation of a proton-motive force that drives the protons back into the matrix 
and produces energy in the form of ATP (Lowell and Flier, 1997). 
1.1.2 Brown adipose tissue (BAT) 
Morphologically, BAT differs from WAT because of its rich vasculature and 
numerous un-myelinated nerves, which provide sympathetic stimulation to the 
adipocytes (Nnodim and Lever, 1988). Opposite to the single large lipid droplet found in 
white adipocytes, brown cells contain smaller lipid droplets and a large number of 
mitochondria (Weber, 2004), giving the characteristic colour of this tissue. The primary 
role of BAT is to convert nutrients into chemical energy in the form of heat (Cannon and 
Nedergaard, 2004). This role has given mammals an evolutionary advantage, which is to 
survive and to be active during periods of nocturnal or hibernal cold, to survive the cold 
stress of birth and probably to survive on diets low in essential macronutrients, such as 
protein (Cannon and Nedergaard, 2004). BAT was thought to be present only in neonatal 
life, in the interscapular region (Gregoire et al., 1998; MacDougald and Mandrup, 2002; 
Spiegelman and Flier, 2001). However, more recent studies provide evidence that brown 
cells exist in adult humans and in several discrete areas and these depots are 
metabolically functional (Nedergaard et al., 2007). Positron emission tomography-
computed tomography (PET-CT) identified the supraclavicular region as the main BAT 
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depot in adult humans, although it is heterogeneous tissue and as it contains cells 
expressing the classical markers for BAT but also cells that do not express these typical 
markers (Cypess et al., 2009; Cypess et al., 2013; Virtanen et al., 2009). Other BAT 
containing regions are the cervical and perirenal areas, which comprise cells expressing 
the classical brown marker genes (Cypess et al., 2013; Nagano et al., 2015; Xue et al., 
2015). Importantly, PET imaging detects higher amounts of BAT in young and lean 
subjects, suggesting that BAT activity is necessary for the natural regulation of body 
weight (Kajimura et al., 2015). As WAT, BAT can also be regulated by environmental 
signals, particularly low temperatures. Interestingly, the original BAT cells, which 
appear in neonatal life, are distinct from the ones that are present or can be induced in 
adults (Wu et al., 2012). 
The heat generated from BAT cells is a product of a complex system consisting 
of mitochondrial biogenesis, energy uncoupling and energy dissipation (Kajimura et al., 
2010). Uncoupling protein 1 (UCP1), a mitochondrial protein, is responsible for this 
unique function of BAT. UCP1 gives the mitochondria an ability to uncouple oxidative 
phosphorylation and utilizes substrates to generate heat rather than ATP. 
1.1.2.1 The thermogenic machinery 
Signals such as “a meal was just consumed”, “too much energy has been stored” 
or “body temperature is lowering” activate a signalling cascade that initiates from the 
ventromedial hypothalamic nucleus (VMN) of the brain (Cannon and Nedergaard, 
2004). Norepinephrine (NE) is released, binds to the β3-adrenergic receptor on the 
plasma membrane of brown adipocytes (Cannon and Nedergaard, 2004) and activates a 
signalling cascade described in Figure 1.1. Phosphorylation of the transcription factor 
cAMP response element-binding protein (CREB) (Thonberg et al., 2002) results in 
expression of genes like UCP1 (Figure 3.15), and activation of MAP kinases, like 
ERK1/2 (Lindquist and Rehnmark, 1998; Shimizu et al., 1997), which inhibits 
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apoptosis, and p38 (Cao et al., 2001), which further stimulates the adrenergic-activated 
UCP1 expression. 
Lipolysis processes and β-oxidation occur in BAT. However, when protons are 
driven back into the mitochondrial matrix through UCP1, the proton gradient is 
dissipated, thereby uncoupling fuel oxidation from ATP synthesis and generating heat 
(Cannon and Nedergaard, 2004). 
1.1.2.2 Physiological roles of BAT in energy metabolism and browning of white 
adipose tissues 
Apart from its thermoregulatory role, BAT plays an important role in regulating 
total body fat. The anti-obesity role became evident when caloric excess could stimulate 
BAT expansion and thermogenesis, known as diet-induced thermogenesis (Rothwell and 
Stock, 1997). Transgenic mice with decreased BAT have glucose intolerance and insulin 
resistance as well as enhanced susceptibility to diet-induced obesity and diabetes 
(Hamann et al., 1993; Hamann et al., 1995; Lowell et al., 1993). Experiments under 
ambient temperatures further supported the above role of BAT as the UCP1 KO mice 
display increased metabolic efficiency (Enerback et al., 1997) and gain more weight 
than WT controls only when housed under thermoneutral conditions (=temperature at 
which the lowest metabolic rate is observed, 29-31
o
 C for mice) (Feldmann et al., 2009). 
Adult humans when exposed to cold, accumulate more BAT in the 
supraclavicular region (Kajimura and Saito, 2014). Despite their multilocular appearance 
and UCP1-positive staining, these areas contain cells that express both brown- and 
white-specific genes (Sharp et al., 2012; Wu et al., 2012). This expansion of BAT 
further resulted in improvement of postprandial insulin sensitivity (Chondronikola et al., 
2014; Lee et al., 2014) and induced energy expenditure (van der Lans et al., 2013; 
Yoneshiro et al., 2013). However, the anti-obesity role of BAT has been disputed as 
studies have shown that upon cold exposure, increased glucose uptake was only reported 
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for BAT and not in other tissues, thus not influencing whole-body insulin sensitivity 
(Orava et al., 2011; Orava et al., 2013; Ouellet et al., 2012). To support this argument, 
studies have shown that the primary substrate for BAT was oxidation of intracellular 
free fatty acids and to a lesser extent plasma substrates (Ouellet et al., 2012), thus 
strengthening the notion of intra-tissue benefits. These contradictory effects resulted 
from differences in the duration of cold exposure and therefore, for future studies, this 
should be considered in order to elucidate the role of BAT in whole-body energy 
homeostasis. 
Newborns have relatively large deposits of BAT. It is believed that with age, but 
probably more with body size, our relative functionality of BAT decreases and 
disappears (Kajimura and Saito, 2014). However, in addition to the supraclavicular and 
perirenal regions of BAT found in humans, islets of BAT are also found in WAT depots 
(Kajimura et al., 2015). These brown-like or beige cells express UCP1 and in rodents, 
they take on a multilocular appearance upon prolonged cold stimulation or elevation of 
intracellular cAMP (Cousin et al., 1992; Young et al., 1984). Although classical brown 
adipocytes derive from a myf-5 positive lineage, similar to skeletal muscle cells (Seale et 
al., 2008), the beige cells do not (Ishibashi and Seale, 2010; Petrovic et al., 2010; Seale 
et al., 2008). 
The beige adipocyte homeostasis may be maintained through two mechanisms. 
First, they can be generated de novo from a population of beige preadipocytes (Wang et 
al., 2013; Wu et al., 2012), which express the early B cell factor-2 (Ebf2), a brown 
preadipocyte marker (Wang et al., 2014). Second, they can be bi-directionally converted 
from and to white adipocytes under the control of environmental temperature or 
sympathetic nerve innervation (Cao et al., 2011; Rosenwald et al., 2013; Ye et al., 2013). 
Although these two theories may seem contradictory, both are still examined to elucidate 
the precise mechanisms that underlie the browning effect of white adipose tissues. The 
appearance of beige cells is “location dependent” (site dependent), as subcutaneous 
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rather than epididymal fat undergoes browning (Ohno et al., 2012; Vitali et al., 2012). 
This is due to increased expression of the BAT-specific marker, PRDM16, in the 
subcutaneous adipose tissue, which has higher density of sympathetic nerves compared 
to epididymal fat (Seale et al., 2011). Further, great variability is reported for the 
browning responses among inbred strains of mice, where C57BL/6J mice have less 
beige in their white fat depots compared to the A/J mice (Collins et al., 1997). 
Environmental cues that control the appearance of beige cells have largely been 
studied and consist of the well-known stimulus cold exposure and subsequent β-
adrenergic activation, exercise, bariatric surgery, cancer and others, which are reviewed 
in Kajimura et al., 2015. Notably, the presence of beige adipocytes in humans is 
inversely correlated with obesity and type 2 diabetes (Kajimura et al., 2015), indicating 
their important role in regulating metabolism. However, the exact mechanisms of 
glucose clearance are not completely understood as beige cells can potentially secrete 
hormones. The latter was proven from the beneficial effects of transplanted 
subcutaneous fat from exercised mice on glucose homeostasis compared to 
transplantations of subcutaneous fat from sedentary mice (Stanford et al., 2015). Further 
evidence on the beneficial effects of beige cells on energy expenditure and propensity 
for weight gain comes from rodent studies. Particularly, mouse strains with high 
propensity for browning of WAT (mice overexpressing Prdm16 and mice with genetic 
ablation of myf-5 resulting in loss of brown adipocytes) are more resistant to diet-
induced obesity (Kajimura and Saito, 2014). 
Overall, BAT and beige cells should be considered more than a heat-generating 
organ/cells. Therefore, their implication in whole-body metabolism could have a 
therapeutic effect in humans with small or actively absent BAT, like obese humans or 
elderly people. While PET-CT detects only the metabolically active BAT and not the 
BAT mass per se, it was shown that young and lean subjects have increased BAT 
activity compared to obese (Lee et al., 2010; Yoneshiro et al., 2011) and elderly 
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(Yoneshiro et al., 2011). Hence, although the precise mechanisms are still unknown, it is 
implied that BAT has a protective role against body fat accumulation and its activity 
decreases with age. 
 
Stressful stimuli can disturb the energy balance, either by mobilizing the energy 
reserves or by increasing the energy pools. The most important mediator in stress 
responses is Corticotropin-Releasing Hormone (CRH) and its implication in regulation 
of whole-body homeostasis will be reviewed in the next section. 
 
1.2 Stress response: CRH and implications in energy homeostasis 
Stress involves external and/or internal challenges that threaten survival (e.g. 
depletion of ATP, increased utilization of substrates, etc). Thus, maintenance of 
homeostasis must be tightly controlled to face these challenges. The integrated stress 
responses are regulated by the Hypothalamo-Pituitary-Adrenal (HPA) axis and its main 
mediator Corticotropin-Releasing Hormone or Factor (CRH or CRF) (Chrousos and 
Gold, 1992). In response to stressful stimuli, CRH initiates and coordinates a series of 
adaptation mechanisms involving the autonomic, endocrine, immune, cardiovascular, 
and reproductive systems. Dysregulation of the stress response can have severe 
physiological and psychological consequences, such as anxiety, anorexia nervosa and 
depression (Sarnyai et al., 2001; Sasaki et al., 1988; Arborelius et al., 1999; Bale, 2005; 
Chrousos and Gold, 1992; de Kloet et al., 2005; Heinrichs and Koob, 2004; Holmes et 
al., 2003; Holsboer, 1999; McEwen, 2004; Zorrilla and Koob, 2004). 
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1.2.1 Corticotropin-Releasing Hormone (CRH) 
CRH is a 41 amino acid peptide (Vale et al., 1981), released from the 
hypothalamus and regulates adrenocorticotropin (ACTH) secretion from the anterior 
pituitary. This, in turn, triggers glucocorticoid release from the adrenal gland (Bale and 
Vale, 2004), which suppresses CRH secretion via a negative-feedback loop. The 
physiological role of CRH is much wider than the central nervous system (CNS) alone 
as CRH is also produced and secreted in the periphery by a plethora of tissues (Table 
1.1). Therefore, CRH exerts a wide spectrum of actions that emphasize its critical role in 
integrating the activity of diverse physiological mechanisms. One such example is the 
effects of CRH on the immune system. Although CRH exerts anti-inflammatory effects 
through glucocorticoids, its production in sites of inflammation suggests a pro-
inflammatory role (Baigent, 2001). In this context CRH appears to be an important 
regulator of inflammatory responses in both autocrine and paracrine ways (Karalis et al., 
1991). 
Table 1.1: Examples of tissues and cells shown to express CRH mRNA and/or 
protein. Taken from Grammatopoulos and Ourailidou, review accepted for publication 
in Current Molecular Pharmacology. 
Tissues/Cells References 
Placenta (Sasaki et al., 1988) 
Endometrium (Makrigiannakis et al., 1997; Makrigiannakis et al., 1995) 
Adrenal (Bruhn et al., 1987) 
Ovary (Mastorakos et al., 1993) 
Testis (Fabbri et al., 1990; Thompson et al., 1987) 
Gut (Suda et al., 1984) 
Anterior pituitary (Suda et al., 1984) 
Lung (Suda et al., 1984) 
Liver (Suda et al., 1984) 
Heart (Muglia et al., 1994) 
Lymphatic organs (Aird et al., 1993) 
Murine splenic T lymphocytes (Muglia et al., 1994) 
Immune cells (Baigent, 2001) 
Skin (Slominski et al., 2001) 
Joints (Crofford et al., 1992) 
Synovium (McEvoy et al., 2001) 
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1.2.2 The CRH family of peptides 
The first mammalian CRH peptide was isolated from ovine hypothalamic 
extracts in 1981 (Vale et al., 1981). Urotensin I in fish (Catostomus commersoni) 
(Lederis et al., 1982) and sauvagine in frogs (Phyllomedusa sauvagei) (Montecucchi et 
al., 1980) consist the ancient paralogs of CRH (Lovejoy et al., 2014). Following CRH 
isolation, a novel family of mammalian CRH-related ligands was discovered. The family 
consists of three members: urocortin 1 (UCN1) (Vaughan et al., 1995), urocortin 2 
(UCN2 or stresscopin-related peptide) (Reyes et al., 2001), and urocortin 3 (UCN3 or 
stresscopin) (Lewis et al., 2001). UCNs are expressed in distinct areas of the brain and 
the periphery (Hillhouse and Grammatopoulos, 2006; Suda et al., 2004), including the 
immune (Kageyama et al., 1999), digestive (Harada et al., 1999), cardiovascular systems 
(Hsu and Hsueh, 2001; Takahashi et al., 2004), and reproductive organs (Yamauchi et 
al., 2005). Although UCNs display only 45% sequence homology with CRH, they exert 
complementary and/or distinct actions (Suda et al., 2004). The interplay between CRH 
and UCNs in physiology and underlying integrated responses are poorly understood. 
Studies employing knockout (KO) animal models revealed that Crh-deficient mice have 
normal behaviour (similar to control animals) under basal conditions, normal increase in 
anxiety-like behaviours after restraint stress or CRH administration into the brain 
(Weninger et al., 1999b) and almost normal feeding and energy homeostasis in basal and 
under restraint stress conditions (Weninger et al., 1999b), suggesting potential 
compensatory roles of UCNs. Despite these normal behavioural characteristics of Crh 
KO mice, the endocrine response, comprised from the release of glucocorticoids, is 
significantly blunted in these mice both under basal and stressful conditions (Bale and 
Vale, 2004). The compensatory roles of UCNs are summarized by the fact that all three 
UCNs have been linked to metabolism regulation (Chen et al., 2006; Kotz et al., 2002; 
Kuperman and Chen, 2008; Li et al., 2007; Zalutskaya et al., 2007), a finding that 
supports the hypothesis of overlapping and possibly synergistic roles. Additionally, in 
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the immune or cardiovascular systems, UCNs have been reported to either mimic CRH 
actions or exert more potent effects (Suda et al., 2004). In contrast, in physiological 
processes controlling the level of anxiety, UCN2 and UCN3 exhibit distinct actions and 
stress-coping characteristics compared to CRH (Suda et al., 2004). Other examples of 
contrasting roles between UCNs and CRH include effects on colonic motility and gastric 
emptying (Suda et al., 2004), where UCNs inhibit and CRH stimulates this process.  
The bioactivity of CRH and related peptides is regulated by a circulating 
binding protein, called CRH-binding protein (CRH-BP). It is produced by the liver and 
the placenta and it can either enhance or inhibit the effects of CRH (Linton et al., 1988; 
Potter et al., 1991; Seasholtz et al., 2002; Sehringer et al., 2004). CRH-BP exhibits 
differential selectivity towards CRH and UCNs and also plays additional roles to 
regulate ligand – CRH receptor interaction by increasing the half-life of CRH or UCNs 
and protecting them from degradation and delivering the ligand to the receptors in target 
tissues (Seasholtz et al., 2002). Moreover some reports raise the possibility that CRH-BP 
might possess intrinsic bioactivity on its own (Seasholtz et al., 2002). 
1.2.3 CRH Receptor subfamilies 
Signals from CRH and UCNs are transduced across the cell membrane through 
activation of two types of receptors, termed CRH receptor 1 (CRHR1) and CRH 
receptor 2 (CRHR2), which are encoded by different genes (Hillhouse et al., 2002). Both 
belong to the family of seven transmembrane domain (7TMD) G protein-coupled 
receptors (GPCRs, family B) (Chang et al., 1993). The ligands for B1 subfamily 
receptors (receptors for “brain-gut” neuropeptides) are polypeptide hormones that act in 
a paracrine and/or autocrine manner, including secretin, glucagon, vasoactive intestinal 
peptide, CRH and parathyroid hormone. The homology between CRHR1 and CRHR2 is 
71% on the amino acid level (Lovenberg et al., 1995). All members of the B1 family of 
GPCRs have multiple coding exons, possibly due to gene duplication during evolution 
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(Lovejoy et al., 2014). Subsequent alternative splicing produces several receptor 
subtypes for both CRHRs, which are expressed in various tissues: CRHR1α (main 
functional receptor), CRHR1β, CRHR1c-h and CRHR2α, CRHR2β and CRHR2γ (Chen 
et al., 1993; Grammatopoulos et al., 1999; Kostich et al., 1998; Liaw et al., 1996; 
Pisarchik and Slominski, 2001; Ross et al., 1994; Valdenaire et al., 1997). 
Despite the great homology between CRHRs, considerable divergence is 
exhibited at their N-termini (only 40% sequence similarity), consistent with their 
pharmacological characteristics (Grammatopoulos and Chrousos, 2002). CRHR1 binds 
CRH as well as UCN1, with equivalent high affinity, but not UCN2 and UCN3 (Figure 
1.2). In contrast, all UCNs are the natural ligands for CRHR2, which binds them with 
significantly higher affinity compared to CRH (Chen et al., 1993; Hsu and Hsueh, 2001; 
Lewis et al., 2001; Lovenberg et al., 1995; Reyes et al., 2001; Vaughan et al., 1995). 
 
Figure 1.2: CRHRs’ pharmacological characteristics. CRHR1 recognizes and binds 
CRH and UCN1 with equivalent high affinity (grey arrows), but not UCN2 and UCN3, 
and CRHR2 binds all thee UCNs with significantly higher affinity (grey arrows) than 
CRH (black arrow). Specific amino acid signatures determine ligand binding affinity: 
proline (P) and alanine (A) residues (coloured red) are found only in CRHR2 selective 
ligands, UCN2 and UCN3, while the CRHR non-selective peptides contain an invariant 
arginine (R) and an acidic (E or D) amino acid (coloured blue). Taken from 
Grammatopoulos and Ourailidou, review accepted for publication in Current Molecular 
Pharmacology. 
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Both CRHRs are widely distributed in the central nervous system (CNS) and the 
periphery. CRHR1 is expressed in the pituitary corticotrophs, where its CRH-dependent 
activation induces pro-opiomelanocortin (POMC) gene transcription and subsequent 
ACTH secretion (Chen et al., 1993; Hsu and Hsueh, 2001; Lewis et al., 2001; Lovenberg 
et al., 1995; Reyes et al., 2001; Vaughan et al., 1995). Levels of CRHR1 are also 
detected in other brain areas (Van Pett et al., 2000) and the periphery (Hillhouse and 
Grammatopoulos, 2006). The expression pattern of CRHR2 differs from that of CRHR1. 
Although, it is detected in the CNS (Kostich et al., 1998; Van Pett et al., 2000), it does 
not co-localize with CRHR1, therefore suggesting that these receptors exert distinct 
roles. In the periphery, CRHR2 has been detected in skeletal, smooth and cardiac muscle 
(Hillhouse and Grammatopoulos, 2006). The diverse and distinct physiological functions 
of CRHR1 and CRHR2 were confirmed by the Crhr1 and Crhr2 KO mouse models, 
which showed different and sometimes opposite phenotypes. Whilst Crhr1 KO mice 
display decreased anxiety-like behaviour and impaired stress response (Smith et al., 
1998; Timpl et al., 1998), Crhr2 deficient mice show increased anxiety-like behaviour, 
accelerated HPA axis response to stress, and impaired cardiovascular function (Bale et 
al., 2000; Coste et al., 2000; Kishimoto et al., 2000). 
CRHRs exert their actions upon ligand binding, which allosterically changes the 
receptor and initiates G protein coupling (Grammatopoulos, 2012). The CRHRs 
preferentially couple to the Gs-adenylyl cyclase signalling pathway, but also exhibit 
alternative coupling to and activation of other G proteins such as Gi, Go, Gq and Gz 
(Figure 1.3) (Chen et al., 1986; Grammatopoulos et al., 2001). Interestingly, not only the 
CRHRs have the ability to bind to different G proteins, but also the pattern of G protein 
activation is unique for each tissue and controlled by tissue-specific mechanisms 
(Grammatopoulos and Ourailidou, review accepted for publication in Current Molecular 
Pharmacology). Further downstream signalling molecules include the protein kinases A 
(PKA), PKC, MAP kinases p38 and ERK1/2 and also signalling molecules such as Ca
2+ 
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and nitric oxide synthase (NOS) (Brar et al., 2004a; Cantarella et al., 2001; Kiang, 1997; 
Ulisse et al., 1990). 
 
Figure 1.3: CRHR signalling. Upon CRH or CRH-like peptides binding to CRHRs, a 
plethora of downstream signalling cascades is activated in a tissue-specific manner. AC 
= adenylyl cyclase, GC = guanylyl cyclase, GDP = guanosine diphosphate, GTP = 
guanosine triphosphate, MAPK = MAP kinase, NOS = nitric oxide synthase, PKA = 
protein kinase A, PKC = protein kinase C, PLC = phospholipase C, sGC = soluble GC, 
NF-κB = nuclear factor kappa-light-chain-enhancer of activated B cells. Modified from 
(Grammatopoulos and Chrousos, 2002). 
 
1.2.4 Metabolic roles of CRH 
The CRH family of neuropeptides also plays an important role in the regulation 
of food intake (Bradbury et al., 2000; Contarino et al., 2000; Cullen et al., 2001; Spina et 
al., 1996), anxiety (Britton et al., 1986; Stenzel-Poore et al., 1994), and stress (Vaughan 
et al., 1995), as well as stimulation of sympathetic outflow (Brown et al., 1982; 
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Udelsman et al., 1986), therefore suggesting their involvement in energy balance. The 
first indirect indications of CRH metabolic actions arose in 1990 (Rothwell, 1990) and 
included experiments with adrenalectomized genetically obese rodents, which displayed 
reduced food intake, body weight gain and increased metabolic rates evident from the 
increased thermogenesis. However, this role of CRH in metabolism was almost 
invalidated when Muglia et al. (Muglia et al., 1995) generated the Crh KO mouse. These 
mice display normal body weight gain and food intake relative to their control (wild-
type, WT) littermates, when allowed ad libitum access to food. Similarly, the 
observation that Crh KO and WT mice exhibit indistinguishable anorectic responses to 
restraint stress (Swiergiel and Dunn, 1999) could emphasize the importance of other 
modulators, such as urocortins, in the control of food intake. 
Further, eating disorders, such as anorexia nervosa, can arise from dysregulation 
of the HPA axis (Rothwell, 1990). Stress-induced anorexia begins when CRH is released 
after a stressful stimulus (Kuperman and Chen, 2008). Acute central administration of 
CRH causes hyperglycemia (Rothwell, 1990) (Table 1.2), while chronic infusions alter 
the energy balance markedly in male rats, whereas no effects are seen in females (Rivest 
et al., 1989). Other differences are observed between obese and lean animals, with the 
obese being more responsive to CRH-induced suppression of food intake and activation 
of brown fat thermogenesis than their leaner controls (Rothwell, 1990). Finally, a 
functional link between CRH and leptin has been described, as leptin administration 
increases hypothalamic CRH expression (Schwartz et al., 1996; Huang et al., 2006) and 
release (Costa et al., 1997). However, since corticosterone levels were unaffected after 
leptin injections, it is suggested that leptin actions are independent of the HPA axis 
(Harris, 2010). Simultaneous injections of leptin and CRH receptor antagonist (alpha-
helical CRH 9-41) prevented leptin-induced hypophagia (Uehara et al., 1998; Gardner et 
al., 1998). The elevated CRHR2 expression after leptin administration (Figure 1.4) 
indicated that this receptor may mediate the effects of leptin (Huang et al., 2006; 
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Nishiyama et al., 1999; Masaki et al., 2003). However, studies using the Crhr2 KO 
mouse showed that CRHR2 is not essential for the anorectic effects of leptin (Harris, 
2010). Due to compensatory mechanisms that might have developed in mice with global 
Crhr2 deficiency (Harris, 2010), further studies are needed in order to elucidate the role 
of CRHRs in regulation of leptin effects. 
Considerable evidence supports the effects of CRH on both energy intake and 
energy utilization. Chronic central CRH infusions attenuate weight gain by reducing 
food intake (Table 1.2). Furthermore, CRH induces energy utilization by activating the 
sympathetic nervous system (SNS) (Cullen et al., 2001): it stimulates thermogenesis in 
brown adipose tissue (BAT), increases uncoupling protein (UCP) 1 in BAT, elevates 
norepinephrine released in CNS as well as increases plasma norepinephrine, increases 
heart rate and stimulates glucocorticoid release. This increases substrates‟ availability in 
liver and muscle and enhances catecholamine-induced lipolysis in adipose tissue. These 
findings suggest that chronic CRH infusions negatively affect the energy balance, 
partially by reducing food intake and partially by activating SNS. 
Table 1.2: Effects of centrally or intraperitoneally (ip) administered CRH and 
UCNs on feeding behaviour of mice. 
 
 
The anorectic effects of CRH, as discussed above, also occur after central or 
intraperitoneal (ip) administration of UCNs (Table 1.2), but without increasing the SNS 
outflow and therefore resulting in a less dramatic state of negative energy balance 
(Cullen et al., 2001; Seres et al., 2004). The metabolic phenotype of Ucn1 KO mice has 
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not been described yet, but it is reported that they have a normal body size and exhibit 
impaired stress response to restraint and cold (Zalutskaya et al., 2007). Ucn2 KO mice 
are characterized by increased tissue-specific insulin sensitivity (Figure 1.4) and 
increased glucose utilization (Chen et al., 2006; Kuperman and Chen, 2008), suggesting 
a role for UCN2 as a modulator of these functions. Furthermore, both Ucn2 (Chen et al., 
2006) and Ucn3 (Li et al., 2007) KO mice are protected against high-fat diet (HFD)-
induced insulin resistance (Table 1.3). Remarkably, Ucn3 KO mice secrete less insulin 
than their control littermates under high glucose-stimulating concentrations and UCN3 
signals through islet CRHR2 to promote insulin secretion (Li et al., 2007), supporting a 
role for UCN3 as an important regulator of β cell insulin release (Figure 1.4). Finally, 
transgenic UCN3
+
 (overexpressing, OE) mice show a lean phenotype complemented 
with increased carbohydrate metabolism, without modulation of the insulin transduction 
signal and up-regulated catabolic processes (Jamieson et al., 2011) (Table 1.3). 
Table 1.3: Metabolic phenotypes and other parameters from mice deficient 
(indicated by KO) in CRH family of peptides and transgenic (indicated by OE) 
mice compared to control mice 
 
(*): (Chotiwat et al., 2010) 
(N): Normal 
(ND): Not Determined 
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Studies with CRHR KO mice show that CRHR2 normally inhibits or dampens 
the stimulatory actions of CRHR1 (Bale et al., 2003). More specifically, Crhr2 KO mice 
exhibit normal basal feeding behaviour and weight gain. However, following a 
challenge, like high-fat diet (HFD) or cold, food intake is reduced, heat production is 
enhanced and fat stores are depleted in the Crhr2 KO mice (Table 1.3). Under HFD, 
Crhr2 KO mice are protected against insulin resistance and the SNS outflow is increased 
(Bale et al., 2003; Kuperman and Chen, 2008). Body mass and food intake are normal in 
the Crhr1 KO mice (Bradbury et al., 2000; Muller et al., 2000), but there is a significant 
disruption of the circadian pattern of food intake. In particular, mice lacking Crhr1 gene 
consume more food during the resting period (light period) (Muller et al., 2000). This 
effect is rescued with glucocorticoid replacement in the drinking water of the mice. 
Further evidence suggests that Crhr1 KO mice have reduced adiposity that could not be 
attributed to differences in food intake and locomotor activity, rather it could result 
partially from increased lipid oxidation in the liver (Sakamoto et al., 2013). Crhr1 KO 
mice have increased insulin sensitivity and when fed HFD, they have reduced weight 
gain and increased energy expenditure (Lu et al., 2015; Sakamoto et al., 2013). 
Recent evidence from in vitro and in vivo experiments (Crhr1 KO mice) 
suggests that CRHR2, and subsequently its ligand UCN2, play a significant role in 
adipose depots development, especially the white adipose tissue (WAT). More 
specifically, they stimulate the differentiation of white adipocytes to brown-like cells, 
whereas CRHR1 and its ligand CRH prevent that, allowing the expression of a white 
phenotype (Lu et al., 2015). These favorable actions of UCN2/CRHR2 are abolished by 
corticosterone replacement in Crhr1 KO mice, thus showing that the brown 
characteristics in the WAT are secondary to the low levels of circulating corticosterone 
(Lu et al., 2015). 
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Figure 1.4: Schematic representation of the proposed roles of central and 
peripheral CRH, UCNs and CRHRs in modulating glucose homeostasis. After a 
stressful stimulus, hypothalamic CRH stimulates glucocorticoid release, which in 
parallel to changes in autonomic activity will modulate skeletal muscle, pancreatic and 
hepatic function. Brain: CRH and UCNs, functioning through CRHR1 and CRHR2, will 
modulate food intake and glucose homeostasis. Leptin increases CRH and CRHR2 
expression levels. Skeletal muscle: UCN2 produced and acting locally on CRHR2 will 
regulate glucose uptake by inhibiting insulin signaling. Pancreas: UCN3, produced by β 
cells, regulates high glucose-induced insulin secretion. Although, both Ucn2 and Ucn3 
deficient mice demonstrate alterations in metabolic liver functions, studies have failed to 
demonstrate hepatic expression of CRH-related peptides or receptors (denoted by „?‟ in 
the liver). Therefore, these observed effects in the mutant mice would seem likely to be 
secondary to their altered energy homeostasis resulting from the direct effects on muscle 
or pancreatic physiology. Modified from (Kuperman and Chen, 2008). 
 
1.2.5 CRH in spleen 
 There is considerable amount of evidence for interactions between the immune 
and the central nervous systems (Jessop et al., 1997). CRH, through activation of the 
HPA axis and subsequent glucocorticoid production, exerts its anti-inflammatory role; 
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whereas peripherally expressed CRH acts as a pro-inflammatory mediator (Karalis et al., 
1991). CRH has been detected in human lymphocytes (Ekman et al., 1993; Stephanou et 
al., 1990), rat thymocytes and splenocytes (Aird et al., 1993; Redei, 1992) and mouse 
spleen (Muglia et al., 1994). Inflammatory diseases, such as arthritis, enhance the 
expression of CRH (Crofford et al., 1992; Jessop et al., 1995; Karalis et al., 1991). CRH 
influences the inflammatory response in various ways: it enhances natural killer (NK) 
cell activity (Carr et al., 1990), it induces rat splenocyte proliferation (McGillis et al., 
1989) and exerts pro-inflammatory effects in inflamed tissues measured by exudate 
volume after carageenin injection (Webster et al., 1996), monocyte infiltration in 
arthritic joints of rats (Crofford et al., 1992) and skin mast cell degranulation and release 
of histamine (Singh et al., 1999; Theoharides et al., 1998). 
 Exogenous administration of CRH in rats reduces spleen weight by 43% 
compared to control animals (Labeur et al., 1995). Splenocyte proliferation is attenuated 
after lipopolysaccharide (LPS) stimulation in CRH-infused animals (Labeur et al., 
1995). Further, using an antisense oligonucleotide complementary to CRH, which 
blocked CRH expression, showed an impaired splenocyte activation upon concanavalin 
A, indicating that endogenous splenic CRH plays a functional role in mediating immune 
cell activation, thus enhancing the pro-inflammatory role of CRH (Jessop et al., 1997). 
 Transgenic mice overexpressing CRH have reduced cellularity in lymphoid 
organs, which reaches 90% in the spleen (Boehme et al., 1997). This resulted from 
impaired development of T and B lymphocytes in primary lymphoid tissues (thymus and 
bone marrow, respectively). On the other hand, mice deficient in Crh exhibit diminished 
inflammatory response to two models of inflammation (carageenin-induced local 
inflammation and turpentine-induced abscess), confirming the pro-inflammatory role of 
peripheral CRH (Karalis et al., 1999; Venihaki and Majzoub, 2002). Upon LPS 
administration in Crh KO mice, a compromised splenic cytokine response was reported 
as measured from tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) (Venihaki 
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et al., 2003). Cultured WT and Crh KO splenocytes have differential responses to 
proliferation, as, although Crh KO basal proliferation was higher compared to WT, Crh 
KO proliferation rates decreased the following days in culture and WT rates remained 
stable (Venihaki et al., 2003). This highlighted the role of endogenous CRH in normal 
proliferation of splenocytes. The absolute numbers of total splenocytes are increased in 
naive Crh KO mice compared to WT (Benou et al., 2005); whereas, similar distributions 
of the major splenic T and B lymphocyte populations are reported between the two 
genotypes (Benou et al., 2005). 
 Other members of the CRH family of peptides, such as UCNs and CRHRs, are 
also expressed in splenic cell populations and their overall contribution to the 
inflammatory stimulation consists mainly in generating a rapid response; whereas the 
released cytokines and other immune mediators activate the HPA axis, which results in 
production of glucocorticoids and a delayed and generalized down-regulation of the 
inflammation (Baigent, 2001). 
 
 Overall, CRH initiates the HPA axis in response to stressful stimuli and thus 
coordinates a series of homeostatic mechanisms. In addition, HPA axis and its 
mediators, such as glucocorticoids, have also been shown to regulate, either directly or 
indirectly, another molecule, Fyn kinase. 
 
1.3 Fyn kinase and the Src kinase family 
Fyn kinase is a member of the large Src family of non-receptor tyrosine kinases, 
which catalyzes phosphorylation of tyrosine residues in proteins (Kefalas et al., 1995). 
Most of them are cytoplasmic enzymes but others, like Fyn, are also localized in the 
membrane and in the nucleus. The Src kinase family consists of nine members: Src, Fyn, 
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Yes, Fgr, Lck, Hck, Blk, Yrk and Lyn kinases (Brickell, 1992; Sudol et al., 1993). 
Interestingly, all members share a common structure (Kefalas et al., 1995) that contains 
four Src homology (SH) domains (Figure 1.5). The SH1 domain contains the enzymatic 
activity and the SH2 and SH3 domains allow them to bind to phosphorylated tyrosine 
residues on their substrates (Boggon and Eck, 2004). The SH4 domain is more variable 
between the members of the family and its post-translational modifications, such as 
myristoylation or palmitoylation, likely participate to their cellular localization (Resh, 
1999). 
 
Figure 1.5: Fyn kinase structure and regulation. SH1 domain contains the catalytic 
activity (denoted by the green “+” symbol). SH2 binds the phosphorylated Tyr(528) at 
the C-terminus, stabilizing the structure in an inactive conformation (denoted by the red 
“-” symbol). Kinases, such as CSK, can phosphorylate Tyr(528), whereas phosphatases 
can dephosphorylate this residue. SH3 domain further represses Fyn activity by binding 
to a polyproline helix between SH2 and SH1. SH4 domain‟s post-translational 
modifications (myristoylation and/or palmitoylation) enable cellular localization and 
trafficking. CSK = C-terminal Src Kinase, PTPs = Protein Tyrosine Phosphatases. 
Modified from (Vatish et al., 2009). 
 
Fyn, in humans, has 3 transcript isoforms. Isoform 1 encodes the FynB protein, 
while isoform 2 encodes the FynT (Saito et al., 2010). The third isoform, FynΔ7, has 
been reported (Goldsmith et al., 2002) but no translated protein has been documented. 
However, in mice, only two isoforms exist, FynT and FynB (Cooke and Perlmutter, 
1989). Both isoforms, as a mixture, are expressed in most tissues (Yamada et al., 2012). 
For example, FynT is more expressed in muscle, white adipose tissue, spleen, heart and 
T cells and FynB is highly expressed in the brain and in the liver. 
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1.3.1 Biological roles of Fyn kinase and its signalling pathways 
Extracellular signals that activate Fyn originate from integrins, G protein-
coupled receptors, specifically Angiotensin II type 1 receptor (Yin et al., 2003), antigen 
and Fc receptors, and cytokine receptors (Sun et al., 2005). The signalling output of this 
activation has several effects on growth and motility pathways. Fyn has been extensively 
studied in its relation to the immune system, especially in T and B cells. Of note is Fyn‟s 
important role during the initial T cell receptor (TCR) activation upon antigen 
recognition (Palacios and Weiss, 2004). Other biological actions include (Saito et al., 
2010; Thomas and Brugge, 1997): proliferation, survival, fertilization, growth factor and 
cytokine receptor signalling, integrin-mediated signalling, cell-cell adhesion, ion channel 
function, platelet activation, axon guidance, entry into mitosis and differentiation of NK-
T cells, oligodendrocytes (Sperber and McMorris, 2001) and keratinocytes. Fyn has also 
been implicated in thymic involution (Nishio et al., 2005). 
 
Figure 1.6: Schematic representation of Fyn signalling pathways. Fyn is localized on 
lipid rafts of the plasma membrane, where it is implicated in the regulation of insulin-
activated pathways (IR and IRS1). Fyn interacts with CD36 and in states of low fatty 
acid availability (Samovski et al., 2015), Fyn phosphorylates LKB1 thus inhibiting 
AMPK. Consequently, ACC is increased and CPT1 is decreased, resulting in a reduced 
state of fatty acid oxidation. Adipogenesis is also down-regulated (left panel) since Thy1 
inhibits Fyn and PPARγ (dotted line = Thy1 indirectly inhibits PPARγ via Fyn). 
Additional cascades where Fyn is implicated are shown in bullets (right panel). 
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Emphasis has been given on the role of Fyn in insulin-stimulated adipogenesis. 
Studies have shown that Fyn is implicated in the regulation of insulin-activated 
pathways (Liu et al., 2005; Saltiel and Pessin, 2003) (Figure 1.6). Firstly, Fyn was 
discovered to be directly associated with insulin-stimulated tyrosine phosphorylated 
insulin receptor substrate 1 (IRS1) and the adaptor protein c-Cbl (Myers et al., 1996; 
Ribon et al., 1998; Sun et al., 1996). Secondly, Fyn participates in the tyrosine 
phosphorylation of caveolin upon insulin stimulation in 3T3L1 cells (Mastick and 
Saltiel, 1997). Caveolin is highly expressed in adipocytes, its expression increases 
during differentiation and it is phosphorylated in result to insulin (Mastick et al., 1995). 
Thirdly, Fyn is located in lipid-raft microdomains, where it co-localized with insulin 
receptor (Dykstra et al., 2003; Liang et al., 2001; van't Hof and Resh, 1997, 1999). 
Furthermore, Fyn associates with flotillin, which is highly expressed in lipid rafts during 
differentiation of 3T3L1 adipocytes. Lastly, Fyn binds to CD36, a fatty acid transporter 
(Bull et al., 1994; Huang et al., 1991; Liu et al., 2005; Samovski et al., 2015). 
Importantly, either pharmacological inhibition of Fyn kinase activity or genetic deletion 
or overexpression of Fyn in 3T3L1 cells highlighted the role of Fyn in modulating the 
differentiation of white preadipocyte cells (Sun et al., 2005; Tse et al., 2013). In vivo 
studies using Fyn KO mice describe a lean phenotype characterized by increased fatty 
acid oxidation and energy expenditure (Bastie et al., 2007), thus strengthening the notion 
of Fyn participating in the regulation of whole-body metabolism. 
Studies reported previously helped elucidate, partly, the molecular pathways of 
Fyn (Figure 1.6). It is known that Fyn negatively regulates AMPK through 
phosphorylation of its upstream kinase, liver kinase B1 (LKB1) (Yamada et al., 2010). 
Inhibition of AMPK, in turn, increases acetyl-CoA carboxylase (ACC) activation and 
subsequently decreases carnitine palmitoyl-transferase (CPT1) levels, affecting the fatty 
acid oxidation pathway (Bastie et al., 2007). Thy1 (or CD90), a cell surface 
glucophosphatidylinositol-anchored glucoprotein, is an upstream inhibitor of Fyn and 
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PPARγ, thus negatively regulating adipogenesis (Woeller et al., 2015). Other Fyn 
signalling pathways that have been identified are the following (Figure 1.6):  Fyn is 
localized downstream of cAMP/PKA (Klinger et al., 2002; Yang et al., 2011) and plays 
a role in activating MAPK (Klinger et al., 2002), Fyn regulates calcium release by 
catalyzing the activation of phospholipase (PL) Cγ to generate pools of inositol 1,4,5 
triphosphate (IP3) (Harr et al., 2010). 
The effects of HPA axis on regulation of Fyn kinase are evident from in vivo 
and in vitro studies. Firstly, behavioural studies have shown that Fyn KO mice display 
increased anxiety (Belzung and Griebel, 2001). Secondly, in vitro studies with T 
lymphocytes concluded that administration of glucocorticoids reduces the expression of 
Fyn kinase (Harr et al., 2010; Lowenberg et al., 2005; Lowenberg et al., 2006). 
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1.4 Thesis aims 
My research project investigated the potential association between CRH and Fyn 
kinase. I based my working hypothesis on data accumulated from in vivo settings with 
Crh and Fyn knockout mice and in vitro experiments. In particular, Fyn was shown to 
regulate β-oxidation (Bastie et al., 2007) and Crh KO mice have increased β-oxidation 
in their white adipose tissues (Karaliota et al., unpublished data; Dr Karalis lab; a project 
in which I was also involved). Secondly, differential behavioural responses, such as 
increased anxiety, where exhibited by mice deficient in peptides of the CRH family and 
Fyn KO mice, indicating that Fyn might be regulated by the HPA axis. Finally, an 
indirect association between CRH and Fyn was postulated by the glucocorticoid 
insufficiency of Crh KO mice (Muglia et al., 1995) and the down-regulation of Fyn by 
glucocorticoids (Harr et al., 2010). The latter places Fyn downstream of the HPA axis. I 
used suitable models, such as the Crh KO mouse (gift from Dr Katia Karalis, 
Biomedical Research Foundation of the Academy of Athens, Greece), complemented 
with in vitro studies to achieve my aims, as listed below: 
1. Determination of Fyn expression in Crh KO mice. 
2. Investigation of alterations in Fyn expression under metabolically challenging 
conditions, such as cold exposure or induced lipolysis, and whether this 
expression was tissue-specific and/or cell-autonomous. 
3. Elucidation of the role of Fyn in brown adipogenesis and its implication in 
CRHR signalling pathways. 
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Chapter 2 
Material and Methods 
2.1 Animals 
2.1.1 Housing, breeding and experimental protocol 
Wild-type (WT) mice (genetic background C57/Bl6) were provided by the 
animal facility, Clinical, Experimental Surgery and Translational Research Center, 
Biomedical Research Foundation of the Academy of Athens (BRFAA). Corticotropin-
Releasing Hormone knockout (Crh KO) mice (genetic background C57/Bl6) were a gift 
from Dr Katia Karalis, Clinical, Experimental Surgery and Translational Research 
Center, BRFAA. 
All studies were approved and performed in compliance with the prefectural 
Veterinary Service of Athens, Greece. Experimentation was performed in the Laboratory 
Animal Facilities of the Biomedical Research Foundation of the Academy of Athens 
(BRFAA), which are approved by the competent authority as breeding (EL25BIO001) 
and experimental (EL25BIO003) facilities. 
Mice were housed and maintained in accordance with the European legal 
framework for the protection of animals used for experimental and other scientific 
purposes (European Directive 86/609/EEC and European Convention 123/ETS). 
Husbandry conditions were in accordance with the current guidelines of international 
organizations, such as the Association for the Assessment and Accreditation of 
Laboratory Animal Care International (AAALAC Int) and the Federation of European 
Laboratory Animal Science Associations (FELASA). 
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Mice were housed in ventilated cages (Techniplast, Varese, Italy) (up to 8 mice 
per cage) under specific pathogen-free (SPF) conditions and constant environmental 
conditions (12:12 hour light: dark cycle (0700-1900), temperature 2220C, and relative 
humidity 4510%). The mice were fed irradiated pellets (2918 Teklad Global 18% 
Protein Rodent Diet, Harlan Laboratories, Indianapolis, USA; 18% protein, 6% fat and 
3.1 kcal/g) and had access to filter-sterile tap water ad libitum. The cage bedding 
comprised corncob granules (REHOFIX®, J. Rettenmaier & Söhne Co., Rosenberg, 
Germany). Cages and bedding were changed once a week. All mice were routinely 
screened (twice a year) under a health-monitoring program, in accordance to the 
Federation of European Laboratory Animal Science Associations‟ recommendations, 
and were classified as free of pathogens. 
All researchers were required to follow mandatory training prior to starting 
animal studies. This training included seminars on animal handling, animal anesthesia 
and analgesia and animal necropsy and histopathology. These seminars discuss warnings 
and safety regulations, safety rules within the facility and procedures to follow in case of 
injury. 
2.1.2 Genotyping 
Despite the glucocorticoid insufficiency (Muglia et al., 1995), Crh KO mice are 
viable and fertile without glucocorticoid replacement. However, litters from 
homozygous mating die within the first 12 hours of life due to lung dysplasia. This 
phenotype can be rescued with glucocorticoid replacement (corticosterone final 
concentration 20 μg/ml; Sigma-Aldrich, USA) in the drinking water of the breeding 
pairs, from day 12 of gestation until weaning day. 
In the case of mating a Crh heterozygous mother with a homozygous father or 
two heterozygous parents will also give rise to Crh KO pups and corticosterone 
replacement is not required because one maternal physiological Crh allele is sufficient to 
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produce the corticosterone needed for survival of litters (Muglia et al., 1995). However, 
identification of the Crh KO pups in this setting requires genotyping due to the mixed 
genotype of the litters and the lack of obvious phenotypes to isolate the Crh KO from 
the Crh heterozygous and the WT littermates. 
2.1.2.1 Tagging, tail clipping and DNA isolation 
Tagging the animals (ear marking, performed under anesthesia) was required to 
identify each individual. DNA was obtained from a small piece of tail (cut under 
anesthesia). Tails were incubated in 200 μl of tail buffer (100 mM Tris-HCl pH 8.5, 200 
mM NaCl, 5 mM EDTA, 0.2% SDS) and Proteinase K 0.1 mg/ml (Sigma-Aldrich, 
USA) overnight at 55
o
C. Proteinase K was deactivated at 95
o
C for 5 minutes. DNA 
isolation continued as follows: 200 μl of Phenol-Chloroform-Isoamyl Alcohol (Sigma-
Aldrich, USA) were added and samples were vortexed, centrifuged at 13,000 rpm for 5 
minutes at room temperature, the upper aqueous phase was collected in 600 μl of ethanol 
(VWR Chemicals, USA), centrifuged at 13,000 rpm for 5 minutes at room temperature, 
the DNA pellet was washed with 500 μl of 70% ethanol in distilled dH2O, centrifuged at 
13,000 rpm for 5 minutes at room temperature, the pellet was air dried and re-suspended 
into 200 μl of dH2O. 
2.1.2.2 Polymerase chain reaction (PCR) 
PCR multiplied the sequence of interest in 25 μl total volume (Table 2.1). 
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Table 2.1: PCR for genotyping. Volume of reagents for the PCR. 
Reagent Volume in μl 
10x Buffer (Invitrogen) 2.5 
MgCl2 50 mM (Invitrogen) 1 
dNTPs 5 mM (Invitrogen) 1 
LM6 primer (10 pmol/μl) 0.5 
LM3 primer (10 pmol/μl) 0.25 
MS1 primer (10 pmol/μl) 0.25 
dH2O 17.3 
Taq Polymerase 5 U/μl (Invitrogen) 0.2 
DNA 2 
 
Table 2.2: PCR for genotyping. Denaturation, annealing, elongation temperatures, and 
incubation times. 
95
o
C 3 min   
55
o
C 1 min 
34 
cycles 
72
o
C 4 min 
95
o
C 1 min 
55
o
C 1 min   
72
o
C 10 min   
4
o
C 10 min   
 
Table 2.3: Primers’ sequence for genotyping. 
Primer Sequence 5' - 3' 
mLM6 GAG CTT ACA CAT TTC GTC C 
mLM3 ATC GCC TTC TTG ACG AGT TC 
mMS1 GCT CAG CAA GCT CAC AGC AA 
 
The Crh KO mouse was generated by targeted disruption in embryonic stem 
cells (Muglia et al., 1994). Homologous recombination resulted in replacement of the 
entire pre-proCRH coding region with the neomycin resistance gene. Primers mLM6 
and mMS1 were designed to bind to the WT allele, outside the coding region, whereas 
the mLM3 primer binds to the neomycin cassette, thus recognizing the Crh KO allele 
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(https://www.jax.org/strain/002783). Under these conditions, a DNA fragment with 400 
bp size characterized the WT, a DNA fragment with 600 bp size characterized the Crh 
KO, since the neomycin cassette is larger in size (bp) compared to the pre-proCRH 
coding region, and two DNA fragments with 400 and 600 bp sizes characterized the Crh 
heterozygotes. 
2.1.2.3 Agarose (1%) gel electrophoresis 
Gel preparation: 1 g of agarose (Sigma-Aldrich, USA) was added in 100 ml of 
TAE 1x (50x TAE: 2 M Tris acetate, 0.05 M EDTA, 1 M Glacial Acetic Acid pH 8.2-
8.4). The mixture was melted and cooled down under tap water until it reached 
approximately 40
o
C. 7 μl of ethidium bromide (Sigma-Aldrich, USA) to visualize the 
DNA were then added. Biorad trays and combs for the gel were used. 
Sample preparation: DNA loading dye 6x (ThermoFischer Scientific, USA) was 
added in 25 μl of PCR product before loading the gel. 1 Kb Plus DNA ladder 
(ThermoFisher Scientific, USA) was used as marker. 
Electrophoresis was performed with the following settings: 120 V for 30 
minutes in TAE 1x. 
Products were visualized under UV light and a picture of the gel was taken 
(Figure 2.1). 
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Figure 2.1: Genotyping results. 1 Kb Plus DNA ladder was loaded on the first lane. 
The samples follow: lane 1-Crh KO mouse at 600 bp, lanes 2 to 6-Crh heterozygous 
mice at 400 and 600 bp and lane 7-WT mouse at 400 bp. 
 
2.1.3 Intraperitoneal injection 
On the day of the experiment, mice were fasted for 3 hours to achieve a 
baseline. This was to avoid potential experimental variations due to random and 
uncontrolled food intake. PBS (Gibco, USA) was injected to the control groups and 
isoproterenol 10 mg/kg in PBS, was injected to the treated groups in a maximum volume 
of 100 μl. Animals were sacrificed 10 minutes later. 
2.1.4 Glucocorticoid replacement 
Corticosterone supplementation (20 μg/ml) in the drinking water of Crh KO 
parents restored blood levels of corticosterone and secured survival of litters (section 
2.1.2). A similar method was used to restore blood corticosterone in 3 months old male 
Crh KO mice for 11 days. 
2.1.5 Cold exposure 
In order to metabolically stimulate (=fatty acid break down and brown adipose 
tissue thermogenesis) the mice, animals were acclimatized at 16
o
C for 24 hours (Lim et 
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al., 2012) before being maintained at 4
o
C for another 24 hours. Mice were then 
sacrificed. 
2.1.6 Sacrifice, blood collection and dissection 
3-hour fasted male mice (3 months old) were anesthetized with sevoflurane 
(Abbvie) and sacrificed by cervical dislocation. Blood (100 μl) was collected retro-
orbitally under anesthesia, prior to sacrifice and samples were kept on ice, before being 
centrifuged at 8,000 rpm for 8 minutes at 4
o
C to collect serum. Dissections included the 
collection of subcutaneous adipose tissue (subAT), epididymal adipose tissue (epiAT), 
brown adipose tissue (BAT), spleen and liver. All samples collected were stored at -
80
o
C until further analysis. 
 
2.2 Cell culture – T37i cell line 
T37i cell line derived from a hibernoma (malignant brown adipose tissue 
tumour) of the transgenic mouse founder 37 carrying a hybrid gene composed of the 
human mineralocorticoid receptor proximal promoter fused to the SV40 large T antigen 
(Zennaro et al., 1998). These cells are capable of differentiating into mature brown 
adipocytes after exposure to insulin and triiodothyronine (T3). Their characteristics 
resembled the ones of mature brown adipocytes: multilocular intracytoplasmic lipid 
droplets and specific adipogenic gene activation (Penfornis et al., 2000), which includes 
uncoupling protein 1 (Ucp1), peroxisome proliferator-activated receptor γ (PPARγ), 
lipoprotein lipase (LPL), adipocyte-specific fatty acid binding protein 2 (aP2) (Buyse et 
al., 2001; Penfornis et al., 2000; Viengchareun et al., 2002; Zennaro et al., 1998). 
2.2.1 T37i culture 
T37i cells were a gift from Dr Marc Lombès, Institut National de la Santé et de 
la Recherche Médicale, Unité 693, Le Kremlin-Bicêtre, France. 
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T37i cells were removed from liquid nitrogen, warmed in a water bath for 2-3 
minutes until thawed, diluted in DMEM/F12 (Gibco, USA) media supplemented with 
10% fetal bovine serum (FBS; Gibco, USA), 1% Penicillin/Streptomycin (5,000 U/ml 
Penicillin and 5,000 μg/ml Streptomycin; Gibco, USA) and 20 mM HEPES (Gibco, 
USA) (=complete DMEM/F12), transferred in a cell culture flask and incubated under 
37
o
C, 5% CO2, 20% O2 for 24 hours. Fresh media was added, unless confluence was 
more than 70% of the flask surface when cells were then split. 
To split T37i cells, media were aspirated and cells were washed with PBS 
(Gibco, USA). 1 ml of 0.25% Trypsin-EDTA (Gibco, USA) was added in a 75 cm
2
 flask 
for 3-4 minutes at 37
o
C. To collect cells and deactivate the trypsin, complete 
DMEM/F12 was added in five volumes of trypsin. Cells were collected in a falcon tube, 
centrifuged at 1,000 rpm for 4 minutes at room temperature and they were re-suspended 
in complete DMEM/F12 and plated in new 75 cm
2
 flasks. 
For cell freezing, cells were centrifuged after trypsinization at 1,000 rpm for 4 
minutes at room temperature. Medium was aspirated and cells were diluted in 45% 
complete DMEM/F12, 45% FBS and 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich, 
USA) and placed in a cryo-freezing container at -80
o
C for 24 hours before being stored 
in liquid nitrogen. 
2.2.2 T37i differentiation 
10
5
 T37i cells per well were plated in 6-well plates. Two days after reaching 
100% confluence, differentiation was initiated. The differentiation medium contained 
complete DMEM/F12, 2 nM T3 (Sigma-Aldrich, USA) and 20 nM insulin (Sigma-
Aldrich, USA) (Penfornis et al., 2000). Fresh differentiation media was added every two 
days until day 11 or 12. 
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2.2.3 SU6656 treatment 
SU6656 is a selective Src kinase family inhibitor, which acts by competing with 
ATP, therefore inhibiting the enzymatic activity of Fyn (Blake et al., 2000). During the 
whole differentiation process, SU6656 10 μM (Cayman Chemical, USA) was added in 
the differentiation media (Bastie et al., 2007). 
2.2.4 Fyn knockdown in T37i cells 
Fyn was silenced using siRNA technology. Control and Fyn knockdown (KD) 
T37i cells were a gift from Dr Elena Tarabra, Albert Einstein, New York, USA. 
 
2.3 Cell culture – Isolation and culture of primary preadipocytes 
Stromal vascular fraction (SVF) was isolated from 3 months old male WT and 
Crh KO mice. The SVF of adipose tissue contains preadipocytes, mesenchymal stem 
cells, endothelial cells, immune cells and blood cells (Riordan et al., 2009; Schipper et 
al., 2012). After 16 hours in culture, media were changed in order to remove all cells 
that were not preadipocytes (Aune et al., 2013). 
2.3.1 Isolation of stromal vascular fraction (SVF) from subcutaneous, epididymal 
and brown adipose tissues 
Subcutaneous, epididymal and brown adipose tissues were dissected from mice 
under sterilized conditions. Briefly, scissors and tweezers were sterilized before the 
experiment and a different pair of scissors and tweezers was used to cut the mouse skin 
and to dissect tissues. Working area and all other instruments (e.g. beakers) were 
cleaned with 70% ethanol. The dissected tissues were placed in PBS (Gibco, USA) at 
37
o
C until further processing. Fat pads were transferred in beakers without PBS. Tissues 
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were finely minced and pieces were transferred in 50 ml falcon tubes, which contained 
the digestion buffer. 10 ml of digestion buffer were used for 12 fat pads (from 6 mice). 
The composition of the digestion buffer for subcutaneous and epididymal 
adipose tissues was as follows: in 10 ml PBS (Gibco, USA) collagenase D (Roche, 
USA) 10 mg/ml was added along with 20 μl of dispase II and 4 μl of CaCl2 2.5 M. The 
solution was filtered with a 0.2 μm filter and warmed at 37oC. 
The digestion buffer for brown adipose tissue contained: 125 mM NaCl, 5 mM 
KCl, 1.3 mM CaCl2, 5 mM glucose and 100 mM HEPES (Gibco, USA) were added in 
PBS (Gibco, USA) to a volume up to 100 ml. Aliquots of the digestion buffer were 
stored at -20
o
C. On the day of the experiment 4% bovine serum albumin (BSA; Sigma-
Aldrich, USA) and collagenase B 1.5 mg/ml (Roche, USA) were added to the buffer. 
The solution was filtered with a 0.2 μm filter and warmed at 37oC. 
Homogenized fat pads were incubated in digestion buffer with collagenase at 
37
o
C for 60 to 75 minutes depending on the size of the pieces, with gentle shake every 
10 minutes. When all tissue was digested, it was filtered through a 100 μm mesh to 
discard adipocytes and undigested pieces of tissue. Collagenase was inactivated with 
three volumes (v/v) DMEM high glucose (4.5 g/l) (Gibco, USA) supplemented with 
10% FBS (Gibco, USA) and 1% Pen/Strep (Gibco, USA) (=complete DMEM). Samples 
were centrifuged at 500 xg for 5 minutes at room temperature. Supernatant was 
discarded and pellet was washed with 20 ml complete DMEM. Samples were 
centrifuged at 500 xg for 5 minutes at room temperature. Supernatant was discarded and 
the pellet (=SVF) was re-suspended in 20 ml complete DMEM and filtered through a 40 
μm mesh to discard any adipocytes that might have pelleted within the SVF. Samples 
were centrifuged at 500 xg for 5 minutes at room temperature. Supernatant was 
discarded and cells were re-suspended in 5 ml of complete DMEM by vigorously 
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pipetting and then plated in 25 cm
2
 flask. Cells were placed in an incubator (37
o
C, 5% 
CO2, 20% O2). 
2.3.2 Preadipocyte culture and splitting 
16-24 hours after the plating of freshly isolated SVF, preadipocytes attached and 
looked like fibroblasts. Since epithelial cells can also attach, they were removed (along 
with other immune and blood cells floating in the media). For this, media was aspirated 
and cells were washed twice with PBS supplemented with 1% Pen/Strep. During each 
wash the flask was shaken vigorously to achieve detachment of the epithelial cells. If the 
confluence of preadipocytes was more than 70% of the flask surface, then cells were 
split. 
To split the preadipocytes, trypsinization was performed as described in section 
2.2.1. Cells were plated in a 75 cm
2
 flask. For the second split, cells were plated in three 
75 cm
2
 flasks and for the final split, cells were cultured in nine 75 cm
2
 flasks. No more 
than three passages were performed to avoid loss of cellular proliferation potency and 
other characteristics, such as inability to differentiate into mature adipocytes. 
2.3.3 Preadipocyte differentiation 
5 x 10
4
 to 10
5 
white and brown preadipocytes were plated per well of 6-well 
plates. Two days after reaching 100% confluence, differentiation was initiated. The 
differentiation medium contained complete DMEM, insulin 5 μg/ml (Sigma-Aldrich, 
USA), dexamethasone 2 μg/ml (Sigma-Aldrich, USA), 0.5 mM 3-isobutyl-
10methylxanthine (IBMX; Sigma-Aldrich, USA), 125 μM indomethacine (Sigma-
Aldrich, USA) and 1 nM T3 (Sigma-Aldrich, USA). Fresh differentiation media was 
added every two days. On the 4
th
 day, differentiation media contained complete DMEM, 
insulin 5 μg/ml and 1 nM T3 (Aune et al., 2013), which was changed every two days 
until day 8 or 10, depending on the maturation status of the adipocytes (numbers of lipid 
droplets accumulated). 
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2.3.4 CRH, UCN2, SU6656 and isoproterenol treatments 
CRH (Bachem, USA) and UCN2 (Bachem, USA) 100 nM (Markovic et al., 
2011; Punn et al., 2006) were added for 5 and 15 minutes in primary brown adipocyte 
cultures at the end of the differentiation process (day 8). 
SU6656 5 μM (Cayman Chemical, USA) was added for 2 hours (Bastie et al., 
2007) in primary brown adipocyte cultures at the end of the differentiation process (day 
8). 
Isoproterenol 0.1 μM (Sigma-Aldrich, USA) (Richelsen and Pedersen, 1987; 
Zhang et al., 2009) and SU6656 5 μΜ (Cayman Chemical, USA) were added in primary 
subcutaneous, epididymal and brown adipocytes at the end of the differentiation process 
(day 10) for 15 and 120 minutes, respectively. 
 
2.4 mRNA quantification 
2.4.1 mRNA isolation 
Total RNA was isolated using Tri Reagent (Sigma-Aldrich, USA). 500 μl of 
reagent were used in a well of a 6-well plate and 1 ml was used for tissues (all volumes 
used below are applicable to 1 ml of Tri Reagent). Cells were homogenized using a 23G 
syringe and tissues were homogenized with the Tissue Master 125 homogenizer (OMNI 
International, USA). The homogenates were left on ice for 5 minutes before adding 200 
μl of chloroform (Sigma-Aldrich, USA), followed by vortex for 15 seconds. Tubes were 
left on ice for 15 minutes and samples were centrifuged at 13,000 rpm for 20 minutes at 
4
o
C. To precipitate the isolated RNA, the upper aqueous phase was transferred in 500 μl 
of isopropanol (ApplichemGmbH, Germany) and stored at -80
o
C for 20 minutes. 
Samples were then centrifuged at 13,000 rpm for 30 minutes at 4
o
C and the pellet was 
washed with 500 μl of ice-cold 70% ethanol in DEPC water (Applichem GmbH, 
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Germany). Samples were centrifuged at 8,000 rpm for 10 minutes at 4
o
C and two more 
washes followed. Pellet was left to air dry and was re-suspended in 20-100 μl of DEPC 
water. 
2.4.1.1 Determination of mRNA amount 
The isolated mRNA was quantified by measuring the absorbance at 260 nm 
using a Nanophotometer (Implen GmbH, Germany). The RNA quality was verified by 
assessing the A260/A280 ratio (with the nanophotometer), which was between 1.8 and 
2.0. 
2.4.2 DNase treatment of isolated mRNA 
Genomic DNA was removed from the samples by using a DNaseI (RNase free) 
kit (Ambion, USA) according to the manufacturer‟s instructions. Briefly, 10x DNaseI 
buffer was added to 1x final concentration in the RNA sample and 1 μl of DNaseI (2 U) 
was used for up to 10 μg RNA. Samples were incubated at 37oC for 30 minutes and 
DNaseI was deactivated at 75
o
C for 10 minutes. 
2.4.3 cDNA synthesis of isolated mRNA 
Reverse transcription was performed using MMLV Reverse Transcriptase 
(Invitrogen, Carlsbad, USA). Up to 2 μg mRNA were used in the following reaction: 2 
μg of mRNA in 6 μl of DEPC water were incubated with 2 μl of 0.3 μg/μl of random 
primers (Invitrogen, Carlsbad, USA) at 75
o
C for 5 minutes. The mix was left to chill on 
ice for 5 minutes and 12 μl of mix B were added (Table 2.4). All samples were 
incubated at 42
o
C for 45 minutes followed by 95
o
C for 10 minutes and finally at 4
o
C for 
10 minutes. 
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Table 2.4: cDNA synthesis of mRNA using the MMLV Reverse Transcriptase. 
Volumes of reagents needed for cDNA synthesis. 
Reagents for mix B Volume in μl 
5x First-Strand Buffer 4 
dNTPs 5 mM 4 
DTT 0.1 M 2 
MMLV 200 U/μl 1 
RNaseOUT
TM
 Recombinant Ribonuclease Inhibitor 40 U/μl 1 
 
2.4.4 Quantitative RT-PCR – SYBR® Green-based quantitative RT-PCR 
2.4.4.1 Primer design 
Primers for SYBR
®
 Green-based quantitative RT-PCR were designed using the 
PrimerQuest Tool from Integrated DNA Technologies (IDT). The target sequence was 
obtained from PubMed nucleotide and the primer specificity was verified by making a 
BLAST search. 
2.4.4.2 SYBR
®
 Green-based quantitative RT-PCR (qRT-PCR) of mRNA 
mRNA expression of genes shown on Table 2.5 were quantified using a SYBR 
Green-based quantitative RT-PCR. The β-actin and cyclophilin genes were used as 
housekeeping genes. Cyclophilin was a more suitable reference gene than β-actin or 
GAPDH for adipocytes undergoing differentiation (Zhang et al., 2014). β-actin, on the 
other hand, was stable in mouse tissues analyses (Lu et al., 2015). 15 μl of mastermix 
(Qiagen, United Kingdom) were mixed with 5 μl of cDNA diluted five times in distilled 
dH2O and incubated using the following program: 50
o
C for 2 minutes, 95
o
C for 10 
minutes and 40 cycles of 95
o
C for 15 seconds and 60
o
C for 60 seconds. In order to 
confirm a single PCR product, melting curve analysis was performed after the 
amplification of the PCR product. 
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Table 2.5: Primers for SYBR
®
 Green qRT-PCR. 
Primer Sequence 5' - 3' 
Amplicon size 
(bp) 
Fyn 
F: ACCTCCATCCCGAACTACAAC 
135 
R: CGCCACAAACAGTGTCACTC 
UCP1 
F: TCTTCTCAGCCGGAGTTTCAGCTT 
86 
R: ACCTTGGATCTGAAGGCGGACTTT 
CIDEA 
F: ATCACAACTGGCCTGGTTACG 
136 
R: TACTACCCGGTGTCCATTTCT 
PRDM16 
F: CAGCACGGTGAAGCCATTC 
87 
R: GCGTGCATCCGCTTGTG 
ACO 
F: TGCCTTTGTTGTCCCTATCCGTGA 
191 
R: TTACATACGTGCCGTCAGGCTTCA 
Hadha 
F: AGCAAGTGTTCAAAGGGCTGAACG 
165 
R: TGTGCTTTACACCGAGGTCCTCAA 
DGAT2 
F: GGCTACCTACCTCAGCTCTC 
161 
R: CTGAAGCCAATGCACGTCAC 
FAS 
F: CTCCGTGGACCTTATCACTA 
201 
R: CTGGAGAGGTTGTAGTCAG 
PPARγ 
F: CAGGCTTGCTGAACGTGAAG 
117 
R: GGAGCACCTTGGCGAACA 
β-actin 
F: CCCAGGCATTGCTGACAGG 
141 
R: TGGAAGGTGGACAGTGAGGC 
Cyclophilin 
F: CATCCTAAAGCATACAGGTCCTG 
165 
R: TCCATGGCTTCCACAATGTT 
 
2.4.4.3 Analysis of qRT-PCR 
The results were analyzed with the ΔΔCt method to calculate the fold mRNA 
expression compared to the basal treatment condition (Livak and Schmittgen, 2001). The 
following equations were used to calculate the relative quantity (RQ): 
ΔCt=Ct(gene of interest) – Ct(housekeeping gene) 
ΔΔCt=ΔCt(sample) – ΔCt(control) 
RQ=2
-ΔΔCt 
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In order to calculate the error, the following equation was used: 
Positive error=2
-(ΔΔCt-SEM)
-RQ 
 
2.5 Protein quantification 
2.5.1 Preparation of cellular protein lysates 
Μedia were aspirated and cells were washed with ice-cold PBS (Gibco, USA). 
100 μl of RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.5% Na-deoxycholate, 
0.1% sodium dodecyl sulfate (SDS), 150 mM NaCl, 2 mM EDTA, dH2O up to 500 ml) 
supplemented with 1% protease (Calbiochem, USA) and phosphatase inhibitor cocktail 
(Sigma-Aldrich, USA) were added per well (6-well plate). Cells were collected with cell 
scrapers and homogenization with a 23G syringe was performed. Lysates were kept on 
ice for 60 to 90 minutes. Samples were centrifuged at 13,000 rpm for 30 minutes at 4
o
C. 
Supernatant was collected and stored at -80
o
C. 
2.5.2 Preparation of protein lysates from animal tissues 
200 to 500 μl of RIPA buffer (same as above) supplemented with 1% protease 
(Calbiochem, USA) and phosphatase inhibitor cocktail (Sigma-Aldrich, USA) were 
added to the tissues. More specifically, 200 μl were used for BAT, 300 μl for subAT and 
epiAT and 500 μl for liver. Homogenization using the Tissue Master 125 homogenizer 
(OMNI International, USA) followed and lysates were kept on ice for 60 to 90 minutes. 
Samples were centrifuged at 13,000 rpm for 30 minutes at 4
o
C. Supernatants were 
collected and stored at -80
o
C. 
2.5.3 Measurement of protein concentration 
Protein concentration was determined using the Bradford assay (BIORAD, 
USA) according to manufacturer‟s instructions. 
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2.5.4 SDS loading buffer lysates 
Protein samples were diluted in dH2O to achieve a final concentration of 15-40 
μg/μl. 5x SDS loading buffer (0.25 M Tris-HCl pH 6.8, 15% SDS, 50% glycerol, 0.01% 
bromophenol blue, 1:20 DTT, 10% β-mercaptoethanol) was added into the lysates. 
Samples were incubated at 95
o
C in a heating block for 5 minutes. 
2.5.5 Gel electrophoresis 
2.5.5.1 Gel preparation 
10% resolving gels (Table 2.6) and stacking gels were prepared. BIORAD 
instruments were used. 
Table 2.6: Volumes for gel preparation. 
Solution components (for 4 gels) Resolving gel Stacking gel 
dH2O 9.9 ml 8.9 ml 
30% bis-acrylamide 8.3 ml 2.2 ml 
1.5 M Tris-HCl pH 8.8 6.3 ml - 
1 M Tris-HCl pH 6.8 - 1.63 ml 
10% SDS 0.25 ml 0.13 ml 
10% ammonium persulfate 0.25 ml 0.13 ml 
TEMED 0.01 ml 0.013 ml 
 
2.5.5.2 Electrophoresis 
Samples and markers (Pink protein ladder; Nippon Genetics Europe GmbH, 
Germany) were loaded onto the gel. Electrophoresis settings were as follows: 30 mA/gel 
for 90 to 120 minutes. The composition of the 10x running buffer was: 14.4 g Glycine, 
30.2 g Tris base, dH2O up to 1 l. 1x running buffer was supplemented with 0.1% SDS 
before use. 
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2.5.6 Immunoblotting 
Proteins were transferred onto a nitrocellulose membrane (GE Healthcare Life 
Sciences, United Kingdom) for 75 minutes at 100 V using BIORAD instruments (wet 
transfer). The composition of the transfer buffer was 1x running buffer and 20% 
methanol. 
2.5.7 Visualization of proteins – Enhanced Chemiluminescence (ECL) detection 
Nitrocellulose membranes were blocked for 1 hour at room temperature with 5% 
milk (Regilait, France) in Tris-buffered saline (TBS 10x: 14 g Tris base, 60 g Tris-HCl, 
87.5 g NaCl, dH2O up to 1 l) containing 0.1% Tween 20 (Sigma-Aldrich, USA) (=TBS-
T). Membranes were incubated with the primary antibody (Table 2.7) diluted in 5% milk 
in TBS-T overnight at 4
o
C under continuous shaking. Membranes were washed three 
times with TBS-T before being incubated with the secondary antibody (horse anti-mouse 
IgG-HRP (Vector, USA) or goat anti-rabbit IgG-HRP (Millipore, USA)) diluted 1:5000 
in 5% milk in TBS-T for 2 hours at room temperature. Membranes were visualized on 
film (Fuji Film, Greece) using ECL (ThermoFischer Scientific, USA). Signal intensities 
were quantified using an Image J software, normalized to GAPDH or β-tubulin signal 
intensities (Table 2.7). β-tubulin was used to normalize the results from the adipose 
tissues‟ lysates because GAPDH showed variability between groups (data not shown). β-
tubulin was also used to normalize results from T37i cells, as previously published 
(Geerling et al., 2014). To re-probe the membranes, membranes were incubated in 
stripping buffer (75 ml dH2O, 4.16 ml 1.5 M Tris-HCl pH 6.8, 20 ml 10% SDS, 700 μl 
β-mercaptoethanol) for 10 minutes at 58-60oC and the blotting process was re-applied. 
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Table 2.7: Primary antibodies and dilutions used for immunoblotting. 
Primary Antibody Dilution 
Fyn (sc-16 Santa-Cruz)  1:500 
phospho-HSL (Ser 563; 4139 Cell Signaling)  1:500 
UCP1 (ab10983 Abcam)  1:1000 
phospho-Akt (Ser473; 9271 Cell Signaling)  1:1000 
total Akt (9272 Cell Signaling)  1:1000 
phospho-ERK1/2 (9106 Cell Signaling)  1:1000 
total ERK1/2 (9102 Cell Signaling)  1:1000 
GAPDH (AM4300 Ambion)  1:4000 
β-tubulin (2146 Cell Signaling)  1:1000 
*The Fyn BD antibody produced two bands (Figure 3.1). 
 
2.6 Oil Red O (ORO) staining 
ORO stock solution: 0.5% (w/v) ORO (Sigma-Aldrich, USA) in isopropanol. 
ORO working solution (freshly prepared): 60% ORO stock solution in dH2O, 
filtered with Whatman filter paper (Whatman, United Kingdom). 
ORO staining was used to visualize the lipid droplets accumulated in 
adipocytes. The protocol used was as follows: cells were fixed in 10% formalin for 15 
minutes, washed three times with PBS, rinsed with 60% isopropanol to remove residual 
aqueous solutions, stained with freshly prepared ORO for 30 minutes, rinsed with 60% 
isopropanol to remove excess ORO stain and washed with PBS. The stained cells were 
stored with PBS at 4
o
 C until microscopy was performed. 
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2.7 Microscopy 
ORO stained adipocytes were visualized with a bright-field microscope (Leica) 
and images were taken with the LAS imaging software. Scale bars were added with the 
Image J software. 
Unstained adipocytes were visualized, when in culture, with a bright-field 
stereoscope (Leica) and images were taken with a digital camera (Nikon). 
 
2.8 Statistical analysis 
Data were analyzed and graphs were prepared using the GraphPad Prism 5 
software. Experiments with the T37i cell line were repeated independently three times to 
allow statistical analysis. Depending on the design of the experiment, comparisons 
among treatment groups were made using Student‟s t-test (when comparing two groups), 
1-way or 2-way ANOVA (when comparing more than two groups) to test for statistical 
significance. In case of ANOVA analysis, Bonferroni post-test analysis was applied to 
perform multiple comparison tests. These parametric tests were based on the assumption 
of normally distributed data. To fulfill this requirement, data of qRT-PCR were log-
transformed prior to analysis. To perform parametric tests with small sample numbers, it 
is important that the measured samples are representative of the population. Small 
sample size is only reasonable under the assumption that the variability within the 
population is small. 
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Chapter 3 
Regulation of Fyn kinase in Crh-deficient mice 
I investigated whether the lack of Crh, using the Crh knockout (KO) mouse, 
affected Fyn expression/function in various tissues that are implicated in metabolic 
processes. Crh KO mice are a suitable tool in my experimental design due to impaired 
hypothalamo-pituitary-adrenal (HPA) axis, which affects behavioural responses to 
stressful stimuli (Bale and Vale, 2004) and is characterized by glucocorticoid 
insufficiency (Muglia et al., 1995). Further, behavioural studies using Fyn KO mice 
(Belzung and Griebel, 2001) and glucocorticoid treatment studies measuring the effects 
on Fyn expression (Harr et al., 2010) suggested that Fyn kinase may be regulated by the 
HPA axis. Therefore, I studied male wild-type (WT) and Crh KO mice (3 months of 
age). Although lack of Crh does not seem to affect the female to male ratio, females 
were excluded from this study as hormonal changes more predominant in females can 
affect fat accumulation, deposition and utilization, and food intake (Wade and Gray, 
1979). Mice were maintained ad libitum (standard diet and ambient temperature are 
defined as normal conditions). Crh KO mice are glucocorticoid insufficient (Muglia et 
al., 1995), therefore, they were also supplemented with corticosterone in their drinking 
water. I also examined whether metabolic challenges, such as cold exposure, which has 
been shown to increase glucocorticoid production (Harper and Austad, 2000; Karp, 
2012) or induced lipolysis, which mobilizes fatty acids similarly to the catabolic role of 
glucocorticoids, could alter Fyn expression, as Fyn is involved, at least partly, in energy 
homeostasis regulation (Bastie et al., 2007; Yamada et al., 2010). Therefore, I examined 
the effects of a cold challenge (4
o
C) or a combination of cold exposure and 
glucocorticoid replacement in the Crh KO mice. Lastly, I investigated the effects of 
intraperitoneal injections of isoproterenol, a lipolytic agent, on lipolytic processes in 
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these mice. Subcutaneous (subAT), epididymal (epiAT) and brown (BAT) adipose 
tissues, spleen and liver were harvested. 
 
3.1 Determination of Fyn expression under normal conditions 
Fyn protein expression in WT and Crh KO white and brown adipose tissues as 
well as in spleen and liver is shown in Figure 3.1. Fyn was significantly reduced in the 
spleen, while other tissues did not show any change in Fyn protein expression. The latter 
did not exclude an effect from global Crh deficiency on Fyn kinase activity, which was 
not measured in this study and could differ between genotypes. 
 
Figure 3.1: Levels of Fyn protein expression in subcutaneous, epididymal and 
brown adipose tissues, spleen and liver. (A) Fyn results are shown, normalized to β-
tubulin, except for the spleen samples, which were normalized to GAPDH. (B) Fyn and 
GAPDH immunoblots for spleen. (Representative immunoblots for the other tissues are 
shown in Fig. 3.12). 40 μg of lysate were used for subAT, epiAT and spleen, whereas 25 
μg were used for BAT and liver. Data are expressed as mean values ± SEM, n=4 for WT 
samples, n=3 for Crh KO samples, t-test: * p<0.05, ns=not significant. 
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3.2 Glucocorticoid replacement and/or cold exposure reduces Fyn 
expression 
Crh KO mice are glucocorticoid insufficient (Muglia et al., 1995). 
Corticosterone supplementation in Crh KO mothers increases blood levels of 
corticosterone and secures the survival of the litters (Muglia et al., 1995). In models of 
glucocorticoid deficiency, such as the Pomc (pro-opiomelanocortin) knockout mice 
(Coll et al., 2005), glucocorticoid replacement (GR) successfully restored blood levels. 
Therefore, it is considered that corticosterone supplementation at a final concentration of 
20 μg/ml in the drinking water of Crh KO mice normalized blood levels to those found 
in WT control animals. ELISA tests determined corticosterone levels and confirmed that 
although baseline (=no supplementation) Crh KO blood levels were significantly 
decreased compared to WT, after supplementation corticosterone levels were restored 
(Karaliota et al., unpublished data). This was evident from the first 24 hours of GR and 
remained stable throughout the experiment (11 days). 
To measure the effects of GR on Fyn expression, mice were sacrificed after 11 
days of GR. Just like glucocorticoids enhance thermogenesis in BAT (Soumano et al., 
2000; Viengchareun et al., 2001), cold exposure has been reported to induce BAT 
thermogenesis (Gasparetti et al., 2003; Lim et al., 2012) and mobilize fat stores in white 
and brown adipose tissues. Therefore, in order to examine mice under this metabolically 
challenging condition, WT and Crh KO mice were placed at 16
o
C for 24 hours in order 
to acclimatize them (Lim et al., 2012) before being placed at 4
o
C for additional 24 hours. 
They were also supplemented with corticosterone or sterile tap water in order to 
specifically investigate the absence of Crh, independently of the effects due to the lack 
of glucocorticoids. I did not observe any differences in Fyn mRNA expression between 
WT and Crh KO mice under normal conditions (Figures 3.2-1A, B, C and 3.2-2E, two 
first columns). Consistently with protein expression (Figure 3.1), Fyn mRNA levels 
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were only significantly reduced in the spleen of Crh KO mice, compared to control 
animals (Figure 3.2-2D). 
 
Figure 3.2-1: Fyn mRNA expression after glucocorticoid replacement and/or cold 
exposure. WT and Crh KO mice were either i) maintained under standard conditions 
(ad libitum access to chow diet and ambient temperatures), or ii) supplemented with 
corticosterone for 11 days or iii) were maintained at 4
o
C (cold challenge) for 24 hours 
with or without corticosterone. Mice were fasted for 3 hours prior to sacrifice and subAT 
(A), epiAT (B) and BAT (C) were dissected. Quantitative RT-PCR was performed for 
Fyn and results were normalized to β-actin. GR=glucocorticoid replacement. Data are 
expressed as mean values ± positive error, n=4 for WT room temperature (RT), Crh KO 
RT and Crh KO cold, n=3 for Crh KO GR RT, n=5 for WT cold and n=2 for Crh KO 
GR cold, 2-way ANOVA with Bonferroni post-test: * p<0.05, ** p<0.01, *** p<0.001. 
Data are normalized to WT RT and the statistical analysis has been performed to the 
control, WT RT, unless otherwise stated by solid lines. 
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Figure 3.2-2: Fyn mRNA expression after glucocorticoid replacement and/or cold 
exposure. Similar description as in Figure 3.2-1. Spleen (D) and liver (E) were 
dissected. 
 
Interestingly, across all tissues investigated, corticosterone supplementation 
significantly decreased Fyn expression levels in Crh KO (Figures 3.2-1 and 3.2-2), 
suggesting that a CRH-dependent mechanism controlled Fyn expression. In addition, 
cold exposure significantly decreased Fyn levels in WT and Crh KO mice. Reduction 
was also measured for the glucocorticoid replaced Crh KO tissues after cold exposure 
compared to Crh KO GR at room temperature and these levels were similar to Crh KO 
cold exposed mice, indicating that this effect was independent of glucocorticoid 
replacement. 
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3.3 Fyn regulates adipogenesis in the T37i brown preadipocyte cell line 
Although Fyn protein levels did not appear to be affected by the lack of Crh in 
mice when animals were maintained in neutral conditions, I uncovered that conditions 
that typically activate thermogenesis, such as glucocorticoid treatment (Soumano et al., 
2000; Viengchareun et al., 2001) or cold exposure (Gasparetti et al., 2003; Lim et al., 
2012), dramatically affected Fyn expression in control mice and this was enhanced by 
the lack of Crh. Interestingly, I observed that Crh KO mice had increased browning 
characteristics in white adipose tissue depots, particularly in the subcutaneous depot 
(Figure 3.3) (Karaliota et al., unpublished data). Therefore, I investigated whether Fyn 
and differences of Fyn expression in BAT, the main tissue for thermogenesis, could 
affect BAT function. 
 
Figure 3.3: Browning of Crh KO subcutaneous white adipose tissue. Hematoxylin 
and eosin staining of WT and Crh KO subcutaneous fat pads. Representative images 
using a bright-field microscope with 10x magnification. (Taken from Karaliota et al., 
unpublished data) 
 
The evolutionary advantage of the appearance of BAT in mammals has been 
previously discussed (chapter 1). One of the functions of this highly specified organ is to 
produce energy from food in the form of heat, a process known as thermogenesis. Major 
role in the process plays uncoupling protein 1 (UCP1), which functions as a 
mitochondrial proton translocator, uncoupling β-oxidative phosphorylation and ATP 
production, resulting in heat release. All mechanisms that induce lipolysis in brown 
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adipocytes also induced thermogenesis, and no thermogenesis can be evoked without 
simultaneously evoking lipolysis (Cannon and Nedergaard, 2004). This pathway has 
been discussed in the general introduction (chapter 1). The genetic switch that 
determines the formation and function of brown adipocytes, originating from a 
progenitor that expresses the myoblast marker myf-5, is PRD1-BF-1-RIZ1 homologous 
domain-containing protein 16 (Prdm16) (Seale et al., 2008). The presence of PRDM16 
causes significant up-regulation of BAT molecular signature genes, such as Ucp1 and 
cell death activator-A (CideA). The expression of PRDM16 in subcutaneous adipose 
tissue regulates a functional thermogenic program (Seale et al., 2011), thus pointing to a 
conserved mechanism that controls brown adipocyte development. 
I first investigated how variations of Fyn expression affected the differentiation 
of the brown preadipocyte cell line, T37i. T37i cell line derived from a hibernoma 
(malignant brown adipose tissue tumour) of the transgenic mouse founder 37 carrying a 
hybrid gene composed of the human mineralocorticoid receptor (MR) proximal 
promoter fused to the SV40 large T antigen (Zennaro et al., 1998). These cells are 
capable of differentiating into mature brown adipocytes after exposure to insulin and 
triiodothyronine (T3). Normally, their characteristics resemble the ones of mature brown 
adipocytes: multilocular intracytoplasmic lipid droplets and specific adipogenic gene 
activation (Penfornis et al., 2000), which includes Ucp1, peroxisome proliferator-
activated receptor γ (PPARγ), lipoprotein lipase (LPL), adipocyte-specific fatty acid 
binding protein 2 (aP2) (Buyse et al., 2001; Penfornis et al., 2000; Viengchareun et al., 
2002; Zennaro et al., 1998). 
To investigate the role of Fyn in these cells, Fyn was either inhibited using a 
pharmacological inhibitor, the SU6656 (Blake et al., 2000), or silenced using siRNA 
technology in these cells. Differentiation processes were assessed by quantitative RT-
PCR of differentiation markers and by visualization of lipid accumulation using Oil Red 
O staining. 
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Figure 3.4 shows representative images of T37i cell differentiation. Staining of 
triglycerides stored in the droplets using Oil Red O, which gives a typical red color, 
assessed differentiation. As expected, no staining was observed in undifferentiated cells 
(day 0). Two days after initiation of differentiation, cells had a globular morphology but 
did not display lipid accumulation (not shown). At day 6 of differentiation, clusters of 
differentiated cells were identified. These clusters became predominant at day 8, as cells 
accumulated lipids. Additionally, the number of droplets per cell had increased, as 
visualized by the red color. More than 70% of the cells contained lipids at day 10 and 
they reached 80% at day 12. 
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Figure 3.4: Oil Red O staining of T37i cells during differentiation. Cells were 
induced to differentiate to mature brown adipocytes. At days 0, 6, 8, 10 and 12, cells 
were washed with PBS, fixed in 10% formalin and stored at 4
o
C with PBS until the Oil 
Red O staining was performed for all plates. Representative images are shown. Images 
were taken using a bright-field microscope (Leica) with 20x magnification. Scale bar is 
40 mm. 
 
As shown in Figure 3.5, cell differentiation was not associated with changes in 
Fyn protein levels. However, blocking Fyn activity using the specific Fyn inhibitor 
SU6656 resulted in reduced differentiation (Figures 3.6, 3.7-1, 3.7-2 and 3.7-3), 
therefore and although Fyn activity was not directly measured, it is likely that Fyn 
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activity played an important role in brown adipose tissue differentiation. As shown in 
Figure 3.6, DMSO had no effect on cell differentiation (as visualized by accumulation of 
lipid droplets); in contrast, cells treated with the Fyn inhibitor showed a reduced number 
of lipid-containing cells, suggesting impaired differentiation. 
 
Figure 3.5: Levels of Fyn protein expression during differentiation of T37i cells. 
Cells were collected at days 0, 4, 8, 10 and 12, and Fyn immunoblots are shown (A). 
Results were normalized to β-tubulin (B). 20 μg of lysate were used. Data are expressed 
as mean values ± SEM, n=3 except for samples from day 10 n=2, 1-way ANOVA with 
Bonferroni post-test: the results are not significantly different. 
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Figure 3.6: SU6656 inhibits the differentiation of T37i cells. From the beginning of 
differentiation, cells were treated either with DMSO (control cells) or SU6656 10 μM. 
Representative images are shown from cells in culture. Images were taken using a 
bright-field stereoscope at (A) day 5, (B) day 9 and (C) day 11 with 10x magnification. 
 
The impaired differentiation of T37i cells treated with SU6656 was also evident 
in gene analysis experiments by using quantitative RT-PCR from cells collected at the 
undifferentiated state (day 0) and fully differentiated cells (day 11) (Figures 3.7-1, 3.7-2 
and 3.7-3). Differentiation markers specific for brown adipocytes, such as Ucp1 (Figure 
3.7-1A), CideA (Figure 3.7-1B) and Prdm16 (Figure 3.7-1C), were decreased (by 86%, 
85%, 43%, respectively) in SU6656-treated cells compared to control cells, indicating 
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less thermogenic capacity of these cells. Aco (acyl-CoA oxidase; Figure 3.7-2D) and 
Hadha (hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA 
hydratase; Figure 3.7-2E) expressions were increased (5- and 1.5-fold, respectively), 
pointing to increased fatty acid oxidation. The expression of Dgat2 (diglyceride 
acyltransferase 2; Figure 3.7-3F) and Fas (fatty acid synthase; Figure 3.7-3G) was 
slightly increased in SU6656-treated cells, which along with the unchanged levels of 
Pparγ (Figure 3.7-3H) suggested that although cells were not differentiating, cells were 
equipped to accumulate lipids. Taken together, these data point to fatty acid oxidation 
being predominant to lipid synthesis and storage in the SU6656-treated cells; and this 
could explain the lack of lipid accumulation in these cells. 
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Figure 3.7-1: Effects of SU6656 on brown adipocyte markers’ gene expression in 
T37i cells. From the beginning of differentiation, cells were treated either with DMSO 
(control cells) or SU6656 10 μM. Quantitative RT-PCR was performed for (A) Ucp1, 
(B) CideA, (C) Prdm16 and results were normalized to cyclophilin. Data are expressed 
as mean values ± positive error, n=3, 2-way ANOVA with Bonferroni post-test: * 
p<0.05, ** p<0.01, *** p<0.001. Data are normalized to control cells at day 0 and the 
statistical analysis has been performed to the control cells at day 0, unless otherwise 
stated by solid lines. 
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Figure 3.7-2: Effects of SU6656 on fatty acid oxidation markers’ gene expression in 
T37i cells. Similar description as in Figure 3.7-1. Quantitative RT-PCR was performed 
for (D) Aco and (E) Hadha. 
 
63 
 
Figure 3.7-3: Effects of SU6656 on lipid storage and synthesis markers’ gene 
expression in T37i cells. Similar description as in Figure 3.7-1. Quantitative RT-PCR 
was performed for (F) Dgat2, (G) Fas and (H) Pparγ. 
 
Because there is always a risk of off-target effect of pharmacological inhibitor, I 
next investigated the effect of Fyn deletion in T37i cells. For this, Fyn was knockdown 
in the T37i cells using the siRNA technology (gift from Dr Elena Tarabra, Albert 
Einstein, NY, USA). 
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As evident in Figure 3.8, Fyn was successfully silenced in T37i cells, as Fyn 
mRNA expression was completely abolished (A) and Fyn protein expression was absent 
(B). 
 
Figure 3.8: Fyn knockdown (KD) in T37i cells. Fyn was silenced with siRNA. (A) 
Fyn mRNA expression normalized to Rpl7 using qRT-PCR in undifferentiated cells. (B) 
Immunoblot for Fyn normalized to GAPDH in untreated cells (=basal), in cells treated 
with the control siRNA (=Ctrl) and in Fyn KD cells without differentiation. (Tarabra‟s 
results) 
 
I next investigated the differentiation processes in Fyn KD cells, compared to 
control cells. This was done by visualizing lipid droplets using Oil Red O (Figure 3.9) 
and by analyzing the main marker of BAT differentiation, Ucp1 (Figure 3.10). 
Consistently with the data with the Fyn inhibitor, silencing Fyn in T37i cells resulted in 
blocking lipid accumulation (Figure 3.9) and a decrease in Ucp1 expression (Figure 
3.10). 
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Figure 3.9: Oil Red O staining of T37i control and Fyn KD cells. Control and Fyn 
KD cells were induced to differentiate to mature brown adipocytes. At days 0, 6 and 8 
cells were washed with PBS, fixed in 10% formalin and stored at 4
o
C with PBS until Oil 
Red O was performed for all plates. Representative images are shown. Images were 
taken using a bright-field microscope (Leica) with 10x magnification. Scale bar is 40 
mm. 
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Figure 3.10: Ucp1 mRNA expression in T37i control and Fyn KD cells. Cells were 
induced to differentiate to mature brown adipocytes and samples were collected at days 
0, 4, 8 and 12. Quantitative RT-PCR was performed for Ucp1 and results were 
normalized to cyclophilin. Data are expressed as mean values ± positive error, n=3, 2-
way ANOVA with Bonferroni post-test: *** p<0.001. Data are normalized to control 
cells at day 0 and the statistical analysis has been performed to the control cells at day 0, 
unless otherwise stated by the solid line. 
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3.4 Isoproterenol increases lipolysis in the white adipose tissue of Crh KO 
mice 
Lipolysis processes were investigated using intraperitoneal injection of 
isoproterenol, traditionally used for these purposes (Girousse et al., 2013; Lucas et al., 
2003; Viswanadha and Londos, 2006). Isoproterenol was injected to mice (10 mg/kg) 
and phosphorylation levels of hormone-sensitive lipase (HSL), one of the major 
enzymes involved in lipolysis (chapter 1) were assessed in subAT, epiAT, BAT and 
liver after 10 minutes. HSL has five phosphorylation sites. Serine 563, serine 659 and 
serine 660 sites are PKA-dependent and increase the hydrolytic activity of HSL 
(Anthonsen et al., 1998); whereas phosphorylation of serine 565 by AMPK inhibits HSL 
phosphorylation at serine 563 resulting in reduced HSL activity (Anthonsen et al., 1998; 
Garton and Yeaman, 1990). ERK-dependent phosphorylation at serine 600 was also 
shown to increase phosphorylation at serine 563 (Greenberg et al., 2001), thus enhancing 
the hydrolytic activity and making this site important during hormonal stimulation, such 
as after insulin or isoproterenol administration. Levels of HSL phosphorylation at serine 
563 were assessed by Western blot and results are shown in Figure 3.11. 
Basal lipolysis was not significantly changed between WT and Crh KO tissues. 
Isoproterenol induced lipolysis in the subcutaneous (Figure 3.11A), epididymal (Figure 
3.11B) and brown (Figure 3.11C) fat pads of WT and Crh KO mice. However, the 
response to isoproterenol in Crh KO was attenuated compared to WT and was abolished 
in BAT (Figure 3.11C). I did not observe any effects in liver (Figure 3.11D), 
consistently with the fact that this tissue is not a major site of lipolysis. 
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Figure 3.11: Levels of phospho-HSL expression in WT and Crh KO mice injected 
with PBS or isoproterenol 10 mg/kg. Mice were fasted for 3 hours before the 
injections and they were sacrificed 10 minutes after the injections. subAT (A), epiAT 
(B), BAT (C) and liver (D) were harvested. Immunoblots are shown for phospho-HSL 
and results were normalized to β-tubulin. 40 μg of lysate were used for subAT and 
epiAT, whereas 25 μg were used for BAT and liver. Data are expressed as mean values 
± SEM, for subAT n=4 for WT PBS and WT isoprot, n=2 for Crh KO PBS and n=3 for 
Crh KO isoprot, for epiAT n=3 for WT PBS and Crh KO isoprot, n=4 for WT isoprot 
and n=2 for Crh KO PBS, for BAT n=4 for WT PBS and WT isoprot, n=2 for Crh KO 
PBS and n=3 for Crh KO isoprot, for liver n=4 for WT PBS, n=3 for WT isoprot and 
Crh KO isoprot and n=2 for Crh KO PBS, 2-way ANOVA with Bonferroni post-test: * 
p<0.05, ** p<0.01, *** p<0.001. Data are normalized to WT PBS and the statistical 
analysis has been performed to the control, WT PBS. 
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To test whether Fyn protein levels were altered or not after isoproterenol 
injection, immunoblots for Fyn were also performed (Figure 3.12). No differences were 
measured between the isoproterenol-treated and control groups and between genotypes. 
 
Figure 3.12: Levels of Fyn expression in WT and Crh KO mice injected with PBS 
or isoproterenol 10 mg/kg. Mice were fasted for 3 hours before the injections and they 
were sacrificed 10 minutes after the injections. subAT (A), epiAT (B), BAT (C) and 
liver (D) were harvested. Immunoblots are shown for Fyn and results were normalized 
to β-tubulin. 40 μg of lysate were used for subAT and epiAT, whereas 25 μg were used 
for BAT and liver. Data are expressed as mean values ± SEM, for subAT n=4 for WT 
PBS and WT isoprot, n=2 for Crh KO PBS and n=3 for Crh KO isoprot, for epiAT n=3 
for WT PBS, WT isoprot and Crh KO isoprot and n=2 for Crh KO PBS, for BAT n=4 
for WT PBS and WT isoprot, n=2 for Crh KO PBS and n=3 for Crh KO isoprot, for 
liver n=4 for WT PBS, n=3 for WT isoprot and Crh KO isoprot and n=2 for Crh KO 
PBS, 2-way ANOVA with Bonferroni post-test: the results are not significantly 
different. Data are normalized to WT PBS. 
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Isoproterenol increases BAT thermogenesis in rodents (Bachman et al., 2002) 
after binding to β-adrenergic receptors. However, in this study, as shown from UCP1 
protein levels (Figure 3.13), I did not observe BAT thermogenesis activation. Possibly, 
the 10-minute treatment was not enough to stimulate UCP1 expression. 
 
Figure 3.13: Levels of UCP1 expression in WT and Crh KO mice injected with PBS 
or isoproterenol 10 mg/kg. Mice were fasted for 3 hours before the injections and they 
were sacrificed 10 minutes after the injections. BAT was harvested. Immunoblots are 
shown for UCP1 and results were normalized to β-tubulin. 25 μg of lysate were used. 
Data are expressed as mean values ± SEM, n=4 for WT samples, n=2 for Crh KO PBS 
and n=3 for Crh KO isoprot, 2-way ANOVA with Bonferroni post-test: the results are 
not significantly different. Data are normalized to WT PBS. 
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3.5 Discussion 
Extensive literature implicates the CRH family of peptides in whole-body 
metabolism. It is widely acknowledged that stress induces anorexia via CRH release 
(Kuperman and Chen, 2008). Other eating disorders, such as anorexia nervosa, can arise 
from HPA axis dysregulations (Rothwell, 1990). Studies that focused on injecting CRH 
centrally, either acutely (Rothwell, 1990) or chronically (Cullen et al., 2001; Rivest et 
al., 1989), unraveled the effects of CRH on both energy intake and energy utilization. 
Briefly, it is suggested that CRH decreases body weight gain (Bornstein et al., 1998; 
Brown et al., 1982; Buwalda et al., 1997; Krahn et al., 1990; Rivest et al., 1989; Rohner-
Jeanrenaud et al., 1989) by reducing food intake (Arase et al., 1988; Krahn et al., 1990; 
Morley and Levine, 1982). On the other hand, CRH‟s effects on energy expenditure are 
mainly via activation of the sympathetic nervous system (Cullen et al., 2001). This 
includes stimulation of thermogenesis in BAT accompanied by increased expression of 
UCP1, induction of norepinephrine release and increase in heart rate and glucocorticoid 
release. Other reports claim that CRH does not only increase body temperature 
(Buwalda et al., 1997; Morimoto et al., 1993), but also transiently increases locomotor 
activity (Buwalda et al., 1997), explaining, at least in part, the effects of CRH on body 
mass. Infusions of UCNs, on the other hand, solely affect (reduce) food intake and do 
not increase sympathetic nervous system outflow as reported for CRH (Cullen et al., 
2001; Seres et al., 2004). 
Deficiency or overexpression of members of CRH family in mice presents 
intriguing metabolic phenotypes (discussed in chapter 1). These mice exhibit either 
normal weight (similar to control animals) and food intake or are leaner compared to 
controls. Additionally, they have distinct responses, such as different levels of insulin 
sensitivity, which are triggered upon metabolically challenging conditions, such as high-
fat diet or stress (Table 3.1). Lastly, UCN2/CRHR2 modulate white adipose tissue 
development as they promote a brown-like (beige) phenotype compared to the white 
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characteristics driven by CRH/CRHR1 (Lu et al., 2015). The latter was also confirmed 
by in vivo studies using the Crhr1 KO mice, which exhibit increased brown 
characteristics in WAT and BAT due to increased CRHR2 activity (Lu et al., 2015). 
Preliminary evidence from the Karalis‟ lab, BRFAA, suggests that the Crh KO 
mice display a lean phenotype compared to their controls, characterized by reduced 
adiposity in all white (subcutaneous and epididymal) adipose pads (Karaliota et al., 
unpublished data). Crh KO mice have a higher metabolic rate (data accumulated from 
indirect calorimetry approach with metabolic cages), increased glucose tolerance and 
insulin sensitivity measured by intraperitoneal injections of glucose and insulin tolerance 
tests (GTT and ITT, respectively). The expanded and functional beige compartment in 
the subcutaneous adipose tissue (Figure 3.3), which promotes an enhanced 
thermogenesis due to increased Ucp1 expression, is another characteristic of Crh KO 
mice. The aforementioned metabolic characteristics along with the lower activity, the 
increased energy expenditure and unchanged food intake compared to WT, make the 
Crh KO resistant to high-fat diet (HFD)-induced obesity. 
Bastie et al. were the first to report the metabolic profile of the Fyn KO mice 
(Bastie et al., 2007). Fyn KO mice have reduced adiposity, accompanied by a reduction 
in adipocyte cell size. Although a recent publication (Tse et al., 2013) suggests 
contradictory results on the effect that causes the reduced adiposity, it is noteworthy that 
the first paper showed smaller adipocytes in the epididymal fat pad, whereas the second 
studied the subcutaneous depot and reported that the total number of adipocytes is 
reduced in Fyn KO mice compared to controls. Fyn KO mice also display reduced 
plasma and intra-tissue triglyceride and non-esterified fatty acid levels and improved 
glucose clearance associated with increased peripheral tissue insulin sensitivity (Bastie 
et al., 2007). Increased fatty acid oxidation in skeletal muscle and white adipose tissues 
and increased energy expenditure, resulted in a lean phenotype. Surprisingly, Fyn KO 
mice on HFD become obese but they remain glucose tolerant and insulin sensitive (Lee 
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et al., 2013). The latter, along with the preferential accumulation of fat within the 
subcutaneous rather than the visceral (epididymal) depot and the reduced inflammatory 
processes within the white depots protected Fyn KO mice from the deleterious effects of 
HFD. An overview of Fyn KO mouse‟s metabolic characteristics and a comparison to 
the metabolic phenotypes of various KO models with deficiency in genes of the CRH 
family of peptides is demonstrated in the table below (Table 3.1). 
 
Table 3.1: Metabolic characteristics of Fyn KO and mice deficient in genes of the 
CRH family of peptides. 
 
(N): Normal 
(ND): Not determined 
 
Strong evidence that supported the rationale to investigate Fyn function in Crh 
KO mice came from the direct regulation of β-oxidation by Fyn (Bastie et al., 2007) and 
the increased β-oxidation pathway in Crh KO mice (Karaliota et al., unpublished data). 
Secondly, under stressful conditions various mouse models lacking genes of the CRH 
family of peptides, such as Crh receptor 1 KO, Crh receptor 2 KO, Crh transgenic and 
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Crh binding protein KO mice (Bale and Vale, 2004), exhibit differential behavioural 
responses, whereas Fyn KO mice display increased anxiety under normal conditions 
(Belzung and Griebel, 2001). Lastly, an indirect association between CRH and Fyn was 
postulated by the glucocorticoid insufficiency of Crh KO mice (Muglia et al., 1995) and 
the direct down-regulation of Fyn by glucocorticoids (Harr et al., 2010), another linking 
point that Fyn is a target of the HPA axis. 
Crh KO mice have been extensively studied for their responses under basal and 
stressful conditions. Although Crh KO mice exhibit adrenocortical atrophy (Muglia et 
al., 1995), they are capable of releasing small amounts of corticosterone under normal 
and stressful conditions, perhaps due to vasopressin which has been shown to act 
synergistically with CRH to augment ACTH release (Bale and Vale, 2004). However, 
this basal and stress-induced endocrine response is significantly blunted compared to 
WT mice (Bale and Vale, 2004). Crh KO mice exhibit normal anxiety to stressful 
stimuli, indicating that CRH is not required for these networks (Dunn and Swiergiel, 
1999; Weninger et al., 1999a). Fyn KO mice, on the other hand, are characterized by 
anxiety and fear under normal conditions (Belzung and Griebel, 2001; Miyakawa et al., 
1994). 
Interestingly, glucocorticoids regulate, either directly or indirectly Fyn kinase 
expression at the mRNA and protein level. The direct effects have been studied in T 
lymphocytes where dexamethasone, a synthetic glucocorticoid, down-regulated Fyn 
expression (Harr et al., 2010). The indirect role of glucocorticoids on Fyn was studied in 
T cells providing evidence of the mechanism that is activated in order for 
glucocorticoids to exert their fast, non-genomic immunosuppressive effects on T cells. 
This indirect role appears when glucocorticoids break down the complex of TCR, 
Lck/Fyn, glucocorticoid receptor and heat-shock protein (Hsp) 90, necessary for T cell 
activation (Lowenberg et al., 2005; Lowenberg et al., 2006). In that way, the role of Fyn 
makes it a potential target for anti-inflammatory therapy as Fyn is tightly connected to 
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mediate TCR signalling (Palacios and Weiss, 2004). Furthermore, glucocorticoid effects 
on immune modulation are either complemented or antagonized by CRH. Particularly, 
CRH-induced activation of the HPA axis and the ensuing glucocorticoid release promote 
anti-inflammatory effects; whereas the peripherally expressed CRH, in various immune 
cells, enhance the inflammatory response (Karalis et al., 1991), thus indicating an 
antagonistic role of CRH to glucocorticoids. 
This study aimed to investigate whether Fyn expression is under the same 
regulatory framework of interactions, as CRH and glucocorticoids. My research has 
provided evidence that Fyn may be unaffected by the global deficiency of Crh, 
associated with adrenal hypofunction and glucocorticoid deficiency, when mice were 
maintained at normal conditions. Both mRNA (Figures 3.2-1 and 3.2-2) and protein 
levels (Figure 3.1) were unchanged between WT and Crh KO mice in a number of 
metabolic tissues (white and brown adipose tissues and liver). There was one notable 
exception, the results from spleen, which are discussed below. 
CRH has a complex role in immunity and inflammation. As discussed above, it 
has been shown that CRH not only attenuates inflammation through stimulation of 
glucocorticoid release (anti-inflammatory role), but also the peripherally expressed CRH 
acts as a pro-inflammatory mediator (Karalis et al., 1991). Due to Crh KO 
glucocorticoid insufficiency (Muglia et al., 1995) and the reported decrease of Fyn by 
glucocorticoids (Harr et al., 2010), I anticipated that Fyn expression in Crh KO spleens 
would be increased or maybe unchanged compared to WT spleens. Unexpectedly, Fyn 
expression was reduced in Crh KO spleens compared to WT (Figures 3.1 and 3.2-2D). 
Interestingly, this effect was greater when circulating corticosterone levels were 
normalized to the WT levels (Figure 3.2-2D). Published reports indicated that exogenous 
corticosterone administration caused reduction in splenic cell populations (Pruett et al., 
2000). The latter in combination with the known down-regulation of Fyn expression by 
glucocorticoids (Harr et al., 2010), could support the greater effect of corticosterone on 
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Fyn expression in Crh KO spleens (Figure 3.2-2D). However, this does not exclude the 
requirement of performing experiments where the absolute numbers of splenocytes and 
major splenic cell populations should be counted after glucocorticoid replacement. 
Under normal conditions, it has been shown that naïve Crh KO spleens have increased 
cellularity compared to control spleens (Benou et al., 2005). This was also evident from 
my experiments, where Crh KO spleen weight was two times heavier compared to WT 
spleens (Figure 3.14A and B), even when spleen weight was normalized to body weight 
(Figure 3.14C; 30% increase). Further, splenic cell subpopulations (mostly T and B 
lymphocytes) were similarly distributed, in absolute numbers, in WT and Crh KO 
spleens (Benou et al., 2005). Overall, the reduced levels of Fyn in Crh KO spleens could 
not be a result of differences in major splenic cellular populations. Rather, it could 
depend on variations of other immune cells, like macrophages and dendritic cells. 
 
Figure 3.14: Crh KO spleen morphology. (A) Image of WT and Crh KO spleens. (B) 
WT and Crh KO spleen weights. (C) Spleen weight normalized to body weight. Data are 
expressed as mean value ± SEM, n=6, t-test: *** p<0.001. 
 
Glucocorticoid replacement has been the preferred method to normalize blood 
levels in glucocorticoid deficient mice, like the Pomc knockout mice (Coll et al., 2005) 
or to restore the levels after adrenalectomy (Sterzer et al., 2004). A dose ranging from 10 
to 30 μg/ml is needed for the survival of pups born from homozygous (Crh KO) parents 
(Muglia et al., 1995). The dose used in this study was 20 μg/ml and successfully 
replaced Crh KO mice (Karaliota et al., unpublished data) and secured survival of litters. 
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Because the effects of Crh deficiency on Fyn could be a result of the subsequent 
glucocorticoid insufficiency, I examined whether glucocorticoid replacement for 11 days 
could have altered Fyn. Notably, in all tissues examined, Fyn was decreased upon 
corticosterone delivery (Figures 3.2-1 and 3.2-2). This suggested that after normalization 
of corticosterone levels to the ones measured in WT mice, only Crh deficiency could 
have an impact on differences recorded. Therefore, this unmasked a CRH-dependent 
mechanism that positively regulated Fyn. However, it should be noted that since the 
levels of urocortins (UCNs) were not determined in this study, their involvement in the 
regulation of Fyn expression/activity cannot be excluded. It has been shown that deletion 
of Crhr1 resulted in variable alterations in the expression of other peptides of the CRH 
family (Bale et al., 2002; Chen et al., 2004a). Additionally, a study using Crhr1 KO 
mice, which are glucocorticoid insufficient (Smith et al., 1998), reported that UCN2 and 
CRHR2 were increased compared to WT littermates in WAT and BAT and that this 
effect was reversed after normalization of circulating corticosterone (Lu et al., 2015). 
This suggested that the UCN system could be altered due to deletion of Crh, as a 
compensatory mechanism, and that this could regulate Fyn expression. Therefore, it is 
essential to elucidate the expression levels of UCNs in the Crh KO mouse, under normal 
conditions and upon glucocorticoid administration, to determine whether CRH directly 
exerts its effects on Fyn or indirectly by inducing alterations in UCNs expression levels. 
Initially thought to be present only in newborns, BAT was recently revealed in 
adults as well (Chatterton et al., 2002; Hany et al., 2002; Okuyama et al., 2002). It is 
active and responsive to cold or β-adrenergic treatment (Cypess et al., 2014; Cypess et 
al., 2009; Cypess et al., 2015; Nedergaard et al., 2007; Saito et al., 2009; van Marken 
Lichtenbelt et al., 2009; Virtanen et al., 2009). When exposed to cold, the sympathetic 
nervous system releases norepinephrine, which binds to β3 adrenergic receptors, 
activating the cAMP-PKA pathway leading to increased Ucp1 expression in BAT and 
heat release (Figure 3.15). Activated PKA in turn phosphorylates lipases, such as HSL, 
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which translocates to lipid droplets (Figure 1.1) and begin the hydrolysis of stored lipids 
(lipolysis) (Zhang et al., 2016). 
 
Figure 3.15: Norepinephrine stimulates heat release in brown adipocytes. A cold 
stimulus activates the SNS, which releases norepinephrine. Upon binding to its receptor, 
the β3-AR, and coupling to Gs proteins, the AC is activated and the cAMP-PKA 
pathway results in increased phosphorylation of CREB. Subsequent transcription of 
Ucp1, translation and translocation to the inner membrane of mitochondria, dissipates 
the proton gradient (H
+
) and uncouples the oxidative phosphorylation from ATP 
synthesis and generates heat. SNS = sympathetic nervous system, NE = norepinephrine, 
β3-AR = β3-adrenergic receptor, AC = adenylyl cyclase, PKA = protein kinase A. 
 
Growing evidence suggests that cold exposure in vivo induces browning in 
WAT (Loncar et al., 1988b; a; Loncar et al., 1986; Young et al., 1984). This 
accumulation of beige cells is reported mostly in the subcutaneous fat depots, whereas 
the epididymal fat is less prone to this “transdifferentiation” (Seale et al., 2011). The 
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critical component that recruits beige cells in the subcutaneous adipose tissue and is 
required for the normal adaptations to cold exposure, is fibroblast growth factor 21 
(FGF21) (Fisher et al., 2012). Karalis group‟s studies in Crh KO mice showed a robust 
increase of beige cells numbers in the subcutaneous compartment, when mice were 
exposed to 4
o
C accompanied by an increase in β-oxidation marker genes (Karaliota et 
al., unpublished data). My experiments had the expected outcome (Figures 3.2-1 and 
3.2-2), that cold induced a significant reduction in Fyn levels due to the increased β-
oxidation. The reported increase in glucocorticoid production after longer or shorter 
periods of exposure to cold (Harper and Austad, 2000; Karp, 2012) could act 
synergistically to the increased β-oxidation pathway, thus also reducing Fyn expression. 
The cold challenge produced similar results in the presence and absence of 
glucocorticoids in Crh KO mice, indicating a different regulation of Fyn at room 
temperature (22
o
C) and at 4
o
C.  
The experimental conditions that I used to unravel the association between CRH 
and Fyn, i.e. glucocorticoid administration and cold exposure, are typical stimulators of 
BAT thermogenesis and of the ensuing UCP1 expression. Glucocorticoids down-
regulate UCP1 (Soumano et al., 2000; Viengchareun et al., 2001), whereas cold 
temperatures enhance UCP1 expression (Gasparetti et al., 2003; Lim et al., 2012). 
However, the role of Fyn has not been elucidated in the regulation of BAT homeostasis. 
Therefore, I sought to determine whether Fyn expression or activity affected BAT 
thermogenesis. Although Fyn protein (Figure 3.1) and mRNA levels (Figures 3.2-1 and 
3.2-2) were unchanged between WT and Crh KO BAT under neutral conditions, Fyn 
kinase activity was not assessed and hence it cannot be excluded that Fyn‟s activity 
differed between the genotypes. To evaluate whether Fyn expression or activity are 
important mediators in brown adipogenesis, I used the T37i brown preadipocyte cell line 
(Zennaro et al., 1998), which possesses typical characteristics of brown adipocytes 
(Buyse et al., 2001; Penfornis et al., 2000; Viengchareun et al., 2002; Zennaro et al., 
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1998). Differentiation of T37i cells was normal as cells accumulated lipids (Figure 3.4). 
In addition, Fyn levels remained stable during the differentiation process (Figure 3.5), 
however, Fyn kinase inhibitor, SU6656, attenuated the differentiation of T37i cells, 
indicating that Fyn kinase activity was essential in this process. T37i cells treated with 
SU6656 did not accumulate lipids in the extent of control cells (Figure 3.6) and this was 
not due to defects in the lipid synthesis (Figure 3.7-3G and H) or lipid storage (Figure 
3.7-3F) capacity of the cells. In fact, SU6656-treated cells had impaired thermogenic 
machinery (Figure 3.7-1A, B and C) accompanied by increased fatty acid oxidation 
markers (Figure3.7-2D and E), which could explain the inability to accumulate lipids in 
a physiological manner. The direct association between Fyn and fatty acid oxidation 
pathway has also been shown with Fyn KO mice, which have increased oxidation of 
lipids (Bastie et al., 2007). 
To ensure that the pharmacological inhibition of Fyn in T37i cells was specific, 
I also used T37i cells where Fyn was silenced with the siRNA technology (Fyn KD 
cells). Similarly to the results obtained with SU6656, Fyn KD attenuated lipid 
accumulation (Figure 3.9) in T37i cells and Ucp1 expression was decreased (Figure 
3.10), indicating that Fyn kinase activity was an important regulator of brown 
adipogenesis. The role of Fyn in adipose tissue differentiation has been suggested (Sun 
et al., 2005; Tse et al., 2013), but only in white adipocytes. This study described a 
similar role in brown adipocyte differentiation. 
The lipolytic agent, isoproterenol, is a non-specific β-adrenergic receptor agonist 
used both in rodent and human studies (Ricci et al., 2005), highlighting its role as a 
sympathomimetic, able to activate BAT thermogenesis. Much effort has been made in 
order to identify the exact mechanisms of isoproterenol-induced lipolysis. It has the 
ability to bind to β-adrenergic receptors and stimulate the cAMP-PKA pathway resulting 
in activation of ATGL and phosphorylation of HSL and the break down of stored lipids. 
The present study showed that Fyn expression was unaffected by isoproterenol exposure 
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(Figure 3.12), at least for the 10-minute treatment that was performed, which is a time-
point traditionally used when studying isoproterenol-induced lipolysis (Girousse et al., 
2013; Lucas et al., 2003). Lipolysis, on the other hand, measured by phosphorylation 
levels of HSL at serine 563, was highly induced in subcutaneous (Figure 3.11A) and 
epididymal (Figure 3.11B) fat pads, followed by a smaller increase in BAT (Figure 
3.11C), whereas liver remained unaffected (Figure 3.11D). Perhaps, this was due to the 
normal appearance of liver with no excess fat (observations during the dissections), 
which usually accumulates in older subjects (Ghosh et al., 2012). The differential 
responses of various adipose tissues to lipolytic agents, such as isoproterenol, or to 
catecholamines, that normally induce catabolic processes in vivo, have been extensively 
studied in humans and rodents. All β-ARs (β1, β2, β3) are expressed in white and brown 
adipose tissues (Boyda et al., 2013) and exert their lipolytic effects upon ligand binding. 
However, β3-AR is the most abundant (Collins et al., 1994); and its expression pattern 
differs between the fat depots. β3-AR is highly expressed in BAT (Muzzin et al., 1991; 
Wajchenberg, 2000) and in beige cells which express UCP1 (Krief et al., 1993), whereas 
epididymal fat not only expresses more β3-AR but also all β-ARs are more active 
compared to subcutaneous adipose tissue (Arner, 1995). Upon norepinephrine injection 
in rats, expression of β3-AR was induced in BAT and WAT (Granneman and Lahners, 
1992) and it stimulated lipolysis in epididymal fat in a degree greater to subcutaneous 
(Morimoto et al., 1997), similarly to isoproterenol (Lacasa et al., 1991). Taken together, 
these reports could explain why in this study, subcutaneous fat (Figure 3.11A) was more 
sensitive to isoproterenol-induced lipolysis compared to epididymal and brown fats 
(Figure 3.11B and C, respectively). In particular, the increased numbers of beige cells in 
the subcutaneous (Crh KO had more compared to WT) rather than in the visceral 
compartment (Karaliota et al., unpublished data) expressed potentially more β3-AR than 
epididymal adipose tissue. Therefore, despite the increased lipolytic capacity of 
epididymal depots compared to subcutaneous, reported in the literature, the metabolic 
phenotype of Crh KO mice resulted in an opposite effect. Furthermore, although BAT 
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was expected to be the most responsive to isoproterenol-induced phosphorylation of 
HSL due to increased β3-AR expression, the duration of the experiment probably was 
not sufficient to potentially activate this lipolytic process. It is noteworthy that 
alterations in the ratio of the anti-lipolytic α2-AR to the lipolytic β-ARs in adipose 
tissues also regulate lipolysis responses (Anthony et al., 2009), thus making it essential 
to elucidate the expression levels of adrenergic receptors in WT and Crh KO adipose 
tissues. 
The discrepant observations in the adipose tissues were of important biological 
significance since differences between various white fat depots also reflect their 
contrasting roles in the pathogenesis of obesity-related disorders (Hamdy et al., 2006). 
Central obesity, i.e. visceral/epididymal fat, is associated with high risk of type 2 
diabetes, dyslipedemia, atherosclerosis and morbidity (Tran et al., 2008). Peripheral 
obesity, which refers to subcutaneous fat depots, is not associated with the above 
pathologies but also improves insulin sensitivity (Snijder et al., 2003b; Tran et al., 
2008). The reasons for these adipose effects consist of: the anatomical location of 
visceral fat, which is in close proximity to the portal vein of liver, thus delivering 
additional free fatty acids, deriving from nutritional imbalance (such as HFD), which 
create an insulin resistant state for this organ (Bjorntorp, 1991; Despres et al., 1995; 
Randle, 1998), and the close proximity of subcutaneous fat with muscle mass at the 
gluteal region, where muscle is an insulin-sensitive tissue (Snijder et al., 2003b; Virtue 
and Vidal-Puig, 2008); the cell-autonomous characteristics, i.e. secreted factors, like 
adipokines, of subcutaneous fat which upon transplantation in visceral depots improved 
body weight and metabolism (Tran et al., 2008); and the effects of adrenal and sex 
steroids influence the accumulation of fat in the visceral depots (Johannsson and 
Bengtsson, 1999; Lonn et al., 1994; Nam et al., 2001; Seidell et al., 1997) rather than in 
the subcutaneous depot. Overall, the subcutaneous compartment of the white fat depots 
in Crh KO mice displayed both the beneficial characteristics on whole-body metabolism 
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and the increased sensitivity to isoproterenol-induced lipolysis, thus making it important 
to unravel in detail the mechanisms that regulate the adrenergic system and the 
expansion capabilities of the white adipose tissues. 
The attenuated response of Crh KO mice compared to WT (Figure 3.11) could 
be a result of the already increased fat utilization as shown from the elevated β-oxidation 
marker genes in the white fat depots of this genotype (Karaliota et al., unpublished data). 
Furthermore, the possibility of Crh KO mice expressing less β3-AR compared to WT in 
their fat depots cannot be excluded. 
In isolated rodent brown adipocytes, isoproterenol stimulated the thermogenic 
pathway (Atgie et al., 1997; Mattsson et al., 2011; Mohell et al., 1983; Shih and 
Taberner, 1995). However, this was not achieved in a study with human subjects 
(Vosselman et al., 2012), which might have been due to a low dose despite the increased 
heart rate and whole-body energy expenditure, likely mimicking the sympathetic 
stimulation. Other sympathomimetics used in human studies could not stimulate BAT 
without the marked effects on the cardiovascular system (Carey et al., 2013; Cypess et 
al., 2012). The dose of isoproterenol used and duration in this experiment failed to 
activate thermogenesis in BAT of WT and Crh KO mice, as shown by the lack of UCP1 
protein expression increase (Figure 3.13). Interestingly, BAT thermogenic activity in 
WT mice was increased four hours following intraperitoneal injection of isoproterenol in 
one study (Bachman et al., 2002), pointing perhaps to the necessity of performing time 
curves. 
To summarize, my studies with a mouse model of global Crh deficiency suggest 
that CRH positively regulated Fyn expression, either directly or indirectly through 
regulation of urocortins expression; and this mechanism was unmasked when mice were 
subjected to metabolically challenging conditions. However, isoproterenol-induced 
lipolysis failed to alter Fyn expression levels, suggesting that this process was either 
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independent of Fyn or longer incubation with isoproterenol was needed. A novel role for 
Fyn kinase was also revealed using the T37i cell line, where Fyn promoted brown 
adipogenesis. Further studies are needed in order to elucidate the acute effects of 
corticosterone replacement on Fyn expression. Indirect calorimetry could provide 
evidence of whole-body energy expenditure after an isoproterenol injection. Subsequent 
in vitro studies will help to further understand how the two molecules, CRH and Fyn, are 
interacting and/or regulating each other. 
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Chapter 4 
Potential roles of Fyn kinase in CRHR signalling and 
lipolysis 
The in vivo experiments using the Crh KO mouse model suggested a positive 
interaction between CRH and Fyn. To further understand the mechanisms that underlie 
this interaction, I studied isolated primary preadipocytes from WT and Crh KO mice‟s 
subcutaneous, epididymal and brown adipose tissues. 
There are several benefits associated with the use of this experimental model. 
Isolation of primary preadipocytes and differentiation to mature adipocytes provided a 
cellular model that maintained its fundamental cellular functions and morphology. In 
particular, preadipocytes from WT and Crh KO mice were able to proliferate in culture 
for four passages and maintained the fibroblast-like appearance of undifferentiated 
adipocytes. Induction of differentiation promoted adipogenesis similarly to cell lines, 
such as the white preadipocyte line 3T3L1 (Green and Meuth, 1974) and the brown 
preadipocyte line T37i (Zennaro et al., 1998). Despite the similar morphology at the 
undifferentiated state, the similar proliferation capabilities and the lack of visible 
differences in differentiation process of WT and Crh KO adipocytes, they remained 
genetically different as they had been exposed to diverse developmental signals due to 
lack of Crh and low levels of corticosterone. Although there is no information about the 
effects of Crh deficiency on preadipocyte fate, it should be noted that the cellular 
content, such as basal phosphorylation levels of proteins and expression of membrane 
receptors, could differ between the two genotypes. This effect is also examined in Crh 
KO tissues. 
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4.1 Signalling pathways activated in differentiated primary brown 
adipocytes 
Signalling molecules, like extracellular signal-regulated kinase (ERK1/2), have 
been extensively studied for their involvement in adipocyte differentiation. ERK1/2, 
particularly, was shown to promote adipogenic differentiation (Bost et al., 2002; Prusty 
et al., 2002; Sale et al., 1995), whereas distinct roles have been attributed to ERK1 and 
ERK2 (Bost et al., 2005; Donzelli et al., 2011). More specifically, using ERK1 KO mice 
showed that ERK1 is necessary for adipocyte differentiation, whereas ERK2 promotes 
proliferation of preadipocytes (Bost et al., 2005). Both isoforms of ERK1/2 have 
important roles during recruitment into the differentiation program and extent of 
maturation in human mesenchymal stem cells (Donzelli et al., 2011). Another signalling 
molecule that is largely implicated in adipocyte differentiation and function is Akt or 
protein kinase B (PKB). Akt is activated downstream of the insulin receptor in insulin-
sensitive tissues, such as adipose tissues, skeletal muscle and liver, and in turn induces 
translocation of the glucose transporter GLUT4 to the cell surface of fat cells and 
skeletal muscle cells, resulting in insulin-induced glucose uptake (Garofalo et al., 2003; 
Gonzalez and McGraw, 2009; Hernandez et al., 2001). 
I examined whether CRH or UCN2 signalling machinery involved Akt and/or 
ERK1/2 regulation in mature brown adipocytes. Both these intracellular protein kinases 
are activated downstream of CRHRs (Grammatopoulos, 2012). Additionally, I 
investigated the effects of the Fyn inhibitor, SU6656 (Blake et al., 2000; Yamada et al., 
2010), on regulating the protein expression of these signalling molecules, in order to 
elucidate a potential interaction between Fyn and CRHRs. 
Primary preadipocytes from WT and Crh KO brown adipose tissues were 
isolated, cultured and induced to differentiate for 8 days, where they reached 
approximately 80% of differentiated cells. Cells were treated with 5 μM SU6656 for two 
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hours before being stimulated with 100 nM CRH or UCN2 for 5 or 15 minutes. 
Phosphorylation of Akt on serine 473, one of CRHRs‟ downstream signalling molecules, 
was measured by immunoblotting (Figures 4.1-1 and 4.1.-2). 
 
Figure 4.1-1: Effects of CRH and UCN2 on phospho-Akt/total Akt ratio in WT and 
Crh KO differentiated primary brown adipocytes. Primary brown preadipocytes were 
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differentiated for 8 days. Cells were treated with CRH (A) or UCN2 (B) 100 nM for 5 
(A and B) and 15 (A and B) minutes. (C) Total Akt normalized to GAPDH. 
Immunoblots of phospho-Akt and total Akt are shown. Results were normalized to 
GAPDH. 15 μg of lysate were used. Data are expressed as mean values ± SEM, n=3 for 
control cells and n=2 for treated cells, 2-way ANOVA with Bonferroni post-test: * 
p<0.05, ** p<0.01, *** p<0.001. Black asterisks (*) denote the significant difference to 
WT control, unless otherwise stated by solid lines. Red asterisks (*), in A and B, denote 
the significant difference to Crh KO control cells. Number signs (#), in A and B, denote 
the significant difference between WT and Crh KO cells. Data are normalized to WT 
control cells. 
 
 
Figure 4.1-2: Effects of CRH and UCN2 on phospho-Akt/total Akt ratio in WT and 
Crh KO differentiated primary brown adipocytes treated with SU6656 5 μM. 
Primary brown preadipocytes were differentiated for 8 days and were treated with 
SU6656 5 μM for 2 hours. Next, cells were treated with CRH or UCN2 100 nM for 5 
(D) and 15 (E) minutes. Similar description as in Figure 4.1-1. 
 
89 
CRH and UCN2 generated a small effect as measured by phospho-Akt/total Akt 
ratio in Crh KO adipocytes. Time course experiments showed significantly increased 
phosphorylation after 15-minute treatment with either CRH or UCN2 in Crh KO 
adipocytes (Figure 4.1-1A and B; 2- or 3.3-fold increase, respectively, compared to Crh 
KO control cells), suggesting that CRHR2 was involved in this process, since UCN2 is 
its natural ligand (Hsu and Hsueh, 2001; Reyes et al., 2001). Further, only Crhr2 was 
expressed in brown fat of WT and Crh KO mice (Karaliota et al., unpublished data). 
Phospho-Akt/total Akt ratio in WT cells was unchanged, indicating that either 
CRH/UCN2 could not activate Akt or there is an impairment in stimulating Akt, perhaps 
in upstream signalling molecules. 
Total Akt levels in Crh KO cells were 2.5-fold higher than WT levels (Figure 
4.1-1C) and remained unchanged during the experimental treatments (not shown). The 
former characteristic could be due to the exposure to different signals during 
development, as mentioned earlier. Additionally, this could have also resulted from the 
differentiation agents added in the media during differentiation of brown adipocytes, 
which consist a stimulus for Akt. This is further supported by the similar total Akt levels 
in WT and Crh KO brown adipose tissues (Figure 4.2 immunoblots). Therefore, only 
Crh KO brown adipocytes showed an increase in Akt protein synthesis upon 
administration of CRH and UCN2. 
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Figure 4.2: Phospho-Akt/total Akt ratio in WT and Crh KO brown adipose tissue. 
BAT was dissected from 3 months old WT and Crh KO mice and immunoblots for 
phospho-Akt and total Akt are shown. Results were normalized to β-tubulin. 30 μg of 
lysate were used. Data are expressed as mean values ± SEM, n=3 for WT samples and 
n=4 for Crh KO samples, t-test: the results are not significantly different. 
 
In contrast, basal phospho-Akt/total Akt ratio was significantly lower in Crh KO 
adipocytes compared to WT (Figures 4.1-1 and 4.1-2), indicating that Crh KO 
adipocytes had impaired activation of Akt. This was unexpected since my hypothesis 
was that the glucocorticoid insufficiency of Crh KO mice (Muglia et al., 1995) would 
remove the inhibitory effects of glucocorticoids on phosphorylation of Akt (Buren et al., 
2002; Long et al., 2003; Shen et al., 2016). This will be discussed further in section 4.3. 
Interestingly, phospho-Akt/total Akt ratio was similar between WT and Crh KO brown 
adipose tissues (Figure 4.2), indicating opposite results to the in vitro setting, suggesting 
that glucocorticoids exert their effects only in vivo and that this effect was diminished in 
culture. 
SU6656 has been shown to inhibit phosphorylation of Akt at serine 473 (Asano 
et al., 2005; Cuneo et al., 2006; Ondrusova et al., 2013) and this is in agreement with my 
results. Inhibition of Fyn activity with SU6656, prior to CRH and UCN2 treatments for 
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5 minutes, almost totally inhibited phospho-Akt/total Akt ratio for both genotypes 
(Figure 4.1-2D). Similar results were obtained during the 15-minute UCN2 treatment 
(Figure 4.1-2E); whereas no change was identified for CRH-treated adipocytes in the 
same time-point. 
Next, phosphorylation of ERK1/2,another downstream signalling molecule of 
CRHR2 (Grammatopoulos, 2012), was examined. Studies have shown that upon ligand 
binding (CRH or UCNs), CRHR2 increases phosphorylation of ERK1/2. This was 
described in various cellular and in vivo settings, such as cardiomyocytes and hearts 
(Brar et al., 2004b; Huang et al., 2009), colorectal cancer cells (Ducarouge et al., 2013) 
and myometrial cells (Karteris et al., 2004). In the brown adipocyte experiment, 
immunoblots of phospho-ERK1/2 levels were carried out and results are shown in 
Figures 4.3-1 and 4.3-2. A time course stimulation showed that CRH for 15 minutes 
activated ERK1/2 in Crh KO adipocytes (Figure 4.3-1A; 2.5-fold increase compared to 
Crh KO control cells), whereas WT levels remained unchanged, indicating that either 
CRH/UCN2 could not activate ERK1/2 or there is an impairment in stimulating 
ERK1/2. The latter could also be attributed to lack of Akt activation in WT brown 
adipocytes, as previously discussed, since Akt has been shown to interact with ERK1/2 
(Zhou et al., 2015). UCN2, on the other hand, exerted a more potent effect and 
significantly increased (4-fold compared to Crh KO control cells) phospho-ERK1/2/total 
ERK1/2 ratio in Crh KO cells at 5 minutes, which was the maximal effect, as levels 
remained stimulated after 15 minutes (Figure 4.3-1B). WT levels showed a delayed 
response to UCN2 and phospho-ERK1/2/total ERK1/2 ratio was elevated by 3.3-fold 
compared to untreated cells (Figure 4.3-1B). Similarly to Akt results, these data confirm 
CRHR2 involvement in activation of ERK1/2. 
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Figure 4.3-1: Effects of CRH and UCN2 on phospho-ERK1/2/total ERK1/2 ratio in 
WT and Crh KO differentiated primary brown adipocytes. Primary brown 
preadipocytes were differentiated for 8 days. Cells were treated with CRH (A) or UCN2 
(B) 100 nM for 5 (A and B) and 15 (A and B) minutes. (C) Total ERK1/2 normalized to 
GAPDH. Immunoblots of phospho-ERK1/2 and total ERK1/2 are shown. Results were 
normalized to GAPDH. 15 μg of lysate were used. Data are expressed as mean values ± 
SEM, n=3 for control cells and n=2 for treated cells, 2-way ANOVA with Bonferroni 
post-test: * p<0.05, ** p<0.01. Black asterisks (*) denote the significant difference to 
WT control, unless otherwise stated by solid lines. Red asterisks (*), in A and B, denote 
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the significant difference to Crh KO control cells. Data are normalized to WT control 
cells. 
 
 
Figure 4.3-2: Effects of CRH and UCN2 on phospho-ERK1/2/total ERK1/2 ratio in 
WT and Crh KO differentiated primary brown adipocytes treated with SU6656 5 
μM. Primary brown preadipocytes were differentiated for 8 days and were treated with 
SU6656 5 μM for 2 hours. Next, cells were treated with CRH or UCN2 100 nM for 5 
(D) and 15 (E) minutes. Similar description as in Figure 4.3-1. 
 
Contrary to total Akt levels (Figure 4.1-1C), total ERK1/2 was unchanged 
between WT and Crh KO cells (Figure 4.3-1C) and remained stable throughout the 
experiment (not shown). Basal phospho-ERK1/2/total ERK1/2 ratio was also similar 
between WT and Crh KO brown adipocytes (Figures 4.3-1 and 4.3-2). Given that the 
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published evidence on glucocorticoid effects on phospho-ERK1/2 identified both an 
inhibitory (Gonzalez et al., 2010; Greenberg et al., 2002) and enhancing role (Kumar et 
al., 2009; Qiu et al., 2001) and the fact that there are no reports on regulation of ERK1/2 
in a Crh deficient environment, no hypothesis could be made on the anticipated ERK1/2 
levels in WT and Crh KO brown adipocytes. Similarly to the in vitro basal total ERK1/2 
levels, brown adipose tissues had similar expression of ERK1/2 (Figure 4.4), suggesting 
that this signalling molecule was not affected by stimulatory signals that activated Akt, 
as discussed previously. 
 
Figure 4.4: Total ERK1/2 in WT and Crh KO brown adipose tissue. BAT was 
dissected from 3 months old WT and Crh KO mice and immunoblots for total ERK1/2 
are shown. Results were normalized to β-tubulin. 30 μg of lysate were used. Data are 
expressed as mean values ± SEM, n=3, t-test: the results are not significantly different. 
 
SU6656 has been shown to exert inhibitory effects on phosphorylation of 
ERK1/2 (Cicha et al., 2014; Garcia-Martin et al., 2013; Tian et al., 2009), similarly to 
what was described for phospho-Akt/total Akt. Although ERK1/2 activation was shown 
to be Fyn-dependent in Crh KO adipocytes after UCN2 treatment for 5 minutes (Figure 
4.3-2D), its activation was Fyn-independent in WT adipocytes (Figure 4.3-2D and E) 
and Crh KO cells during the 15-minute treatments (Figure 4.3-2E). 
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4.2 Isoproterenol and SU6656 effects on lipolysis in differentiated primary 
white and brown adipocytes 
I examined whether the in vivo data (section 3.4) from white and brown adipose 
tissues could be reproduced in vitro and thus if this event was cell-autonomous. 
Isoproterenol is a lipolytic agent (Girousse et al., 2013; Lucas et al., 2003; Viswanadha 
and Londos, 2006) widely used both in vitro and in vivo. Whilst increased fatty acid 
oxidation is mainly thought to be the reason for the lean phenotype of Fyn KO mice, it is 
possible that increased lipolysis could also participate to this phenomenon. To assess the 
lipolytic actions of isoproterenol and SU6656 on differentiated primary white and brown 
adipocytes, phosphorylation levels of HSL at serine 563 (most commonly examined 
phosphorylation site as discussed in section 3.4) were measured. 
Basal lipolysis, assessed by phospho-HSL in PBS-treated cells, was unchanged 
between WT and Crh KO adipocytes (Figure 4.5), similar to the in vivo results (Figure 
3.11). Isoproterenol induced an increase in phospho-HSL levels (Figure 4.5A, B and C); 
and this result was more prominent in epididymal and brown adipocytes (Figure 4.5B 
and C) compared to subcutaneous (Figure 4.5A). This was opposite to the in vivo results 
and might be related to developmental cues that regulate whole-body homeostasis 
(discussed in section 4.3). 
Additionally, phosphorylated HSL was increased in Crh KO cells more than in 
WT, but that was only present in the white and not the brown adipocytes, which 
displayed the opposite effect (Figure 4.5A, B and C). Since isoproterenol is a non-
selective β-adrenergic agonist, the data on WT and Crh KO adipocytes could be a result 
of the different expression of β-adrenergic receptors (β-AR), which will be discussed 
further in section 4.3. These results were not in agreement with the in vivo 
measurements where Crh KO adipose tissues, both white and brown, had an attenuated 
response to isoproterenol compared to WT (Figure 3.11). Further, subcutaneous tissue 
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exhibited the strongest increase in phospho-HSL activation, contrary to the smallest 
effect reported in vitro. Despite the possibility that different expression patterns of 
adrenergic receptors were the main reason for the varying results between WT and Crh 
KO cells or tissues, it is noteworthy that the characteristic metabolic phenotype of Crh 
KO mice consisted the basis for the differences observed between the in vivo and in vitro 
results. 
 
Figure 4.5: Effects of isoproterenol and SU6656 on levels of phospho-HSL 
expression in WT and Crh KO differentiated primary white and brown adipocytes. 
Primary subcutaneous (A, D), epididymal (B, E) and brown (C) preadipocytes were 
differentiated for 10 days and were treated next either with isoproterenol 0.1 μM for 15 
minutes (A, B, C) or SU6656 5 μM for 2 hours (D, E). Immunoblots of phospho-HSL 
are shown. Results were normalized to β-tubulin. 15μg of lysate were used. Data are 
expressed as mean values ± SEM, for subAT and epiAT cells: n=4 for WT PBS and n=2 
or 3 for remaining conditions, for BAT cells: n=3, 2-way ANOVA with Bonferroni post-
test: * p<0.05, ** p<0.01, *** p<0.001. Data are normalized to WT PBS and the 
statistical analysis has been performed to WT PBS, unless otherwise stated by solid 
lines. 
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Controversial results were obtained with SU6656 since it caused a 50% 
reduction in phospho-HSL of WT subcutaneous adipocytes (Figure 4.5D) and it further 
produced an increase in lipolysis of WT epididymal adipocytes (Figure 4.5E), which are 
more sensitive to isoproterenol-induced lipolysis compared to subcutaneous adipocytes 
(Arner, 1995; Lacasa et al., 1991). Moreover, Fyn did not mediate the activation of HSL 
in isoproterenol-treated Crh KO epididymal adipocytes (Figure 4.5E). 
Similarly to the in vivo data (Figure 3.12), Fyn protein expression was not 
affected by any of the agents used on cultured adipocytes (Figure 4.6), indicating that, 
perhaps, this process of induced lipolysis was independent of Fyn expression. 
 
Figure 4.6: Effects of isoproterenol and SU6656 on levels of Fyn expression in WT 
and Crh KO differentiated primary white and brown adipocytes. Primary 
subcutaneous (A, D), epididymal (B, E) and brown (C, F) preadipocytes were 
differentiated for 10 days and were treated next either with isoproterenol 0.1 μM for 15 
minutes (A, B, C) or SU6656 5 μM for 2 hours (D, E, F). Immunoblots of Fyn are 
shown. Results were normalized to β-tubulin. 15 μg of lysate were used. Data are 
expressed as mean values ± SEM, n=2 or 3, 2-way ANOVA with Bonferroni post-test: 
the results are not significantly different. Data are normalized to WT PBS. 
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4.3 Discussion 
Primary cells are a useful tool in research design as they allow experimental 
procedures, which are difficult to perform in vivo, such as investigate the effects of a 
kinase inhibitor on a specific cell type independently of other cell types residing in the 
tissue. Isolating, culturing and differentiating preadipocytes from WT and Crh KO white 
(subcutaneous and epididymal) and brown fat pads provided a cellular model, which 
allowed investigation of CRHR signalling cascades and quantification of responsiveness 
to potential lipolytic agents. These experiments addressed the question of whether Fyn is 
involved in CRHRs signalling. Further, the addition of isoproterenol and SU6656 in the 
culture media provided evidence of their lipolytic effects and whether these effects were 
cell-autonomous and Fyn-mediated. 
To date, there are no reports of CRHR signalling characteristics in brown 
adipocytes. The importance of the role of CRHR in brown adipocyte physiology has 
been highlighted by studies with CRHR knockout mice. Interestingly, these studies have 
confirmed the CRHRs‟ involvement in energy balance via regulation of the sympathetic 
nervous system (SNS) activation and subsequent stimulation of thermogenesis in brown 
fat (Bale et al., 2003; Carlin et al., 2006). These central effects were abolished in the in 
vitro system used in this study, and therefore, the direct effects of peptides were 
investigated independently of the central effects they exert in vivo, thus providing 
another beneficial effect for the primary cell cultures. In this study, the WT and Crh KO 
mice strains used did not express Crhr1 in their brown fat depots (Karaliota et al., 
unpublished data). Crhr2, on the other hand, was expressed and its levels were increased 
in Crh KO compared to control animals (Karaliota et al., unpublished data). 
CRH and UCN2 have been shown to activate Akt through binding to CRHR2 in 
various cellular models. Particularly, CRH stimulated Akt in THP1 human monocytic 
cells (Chandras et al., 2009), whereas UCN2 exerted similar actions in HEK293 kidney 
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cells (Markovic et al., 2011), RM-1 prostate cancer cells (Jin et al., 2011) and ventricular 
myocytes (Walther et al., 2014). Akt, as a signalling molecule has been implicated in a 
variety of processes. The phosphatidylinositol-3 kinase (PI3K)/Akt pathway is involved 
in promoting cell growth, proliferation and cell survival (Altomare and Khaled, 2012; 
Manning and Cantley, 2007). In insulin-sensitive tissues, like skeletal muscle, adipose 
tissue (white and brown) and liver, upon insulin binding, insulin receptor is tyrosine 
phosphorylated and in turn, activates the insulin receptor substrate 1 (IRS1)/PI3K/Akt 
pathway (Shepherd, 2005; Shepherd et al., 1998). This signalling cascade results in 
glucose transport in cells (Cheatham et al., 1994; Hara et al., 1994; Hernandez et al., 
2001; Le Marchand-Brustel et al., 1995; Okada et al., 1994), increases expression of 
glycogen synthase (Shepherd et al., 1995) and decreases lipolysis (Duncan et al., 2007). 
This pathway has also been shown to activate phosphodiesterase 3B (PDE), which 
hydrolyzes cAMP (Jaworski et al., 2007; Wijkander et al., 1998) and thus rendering 
PKA less active in the hydrolysis pathway (described in the general introduction; Figure 
1.1). 
The interplay between Akt and glucocorticoids has been studied on the basis 
that glucocorticoids are responsible for the development of insulin resistance in muscle, 
adipose tissue and liver (Witchel and DeFranco, 2006). It was shown that, in vivo, 
dexamethasone, a synthetic glucocorticoid, diminished insulin-mediated PI3K/Akt 
activation in muscle and liver (Giorgino et al., 1993; Ruzzin et al., 2005; Saad et al., 
1993). In dexamethasone-treated rat adipocytes (Buren et al., 2002) and upon injection 
of dexamethasone in rats (Buren et al., 2008), inhibition of insulin-induced Akt 
phosphorylation has been reported. Furthermore, adrenalectomy, promoting a 
glucocorticoid deficient environment, was associated with enhanced insulin signalling 
and Akt in skeletal muscle (Long et al., 2003). In various other experimental settings, 
where phosphorylation of Akt is not associated with insulin, glucocorticoids have also 
been shown to inhibit its phosphorylation. For example, through inhibition of Akt, 
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dexamethasone inhibits osteoblast remodeling (Shen et al., 2016), impairs neurite 
outgrowth in PC12 cells (Terada et al., 2014) and promotes apoptosis in L6 myoblasts 
(Singleton et al., 2000). Increased glucocorticoid production in rats with chronic renal 
failure, resulted in impaired PI3K/Akt activation (Wang et al., 2007). 
In the present study, increased phospho-Akt/total Akt ratio was measured for 
both treatments, CRH and UCN2 (Figure 4.1-1A and B). This suggested involvement of 
CRHR2, since UCN2 is its natural ligand (Hsu and Hsueh, 2001; Reyes et al., 2001). 
This was also confirmed by the lack of Crhr1 expression in brown adipose tissue of WT 
and Crh KO mice (Karaliota et al., unpublished data). The increased Crhr2 expression in 
Crh KO BAT compared to WT (Karaliota et al., unpublished data) was in agreement 
with a different mouse model, the Crhr1 KO, which expressed elevated Crhr2 in WAT 
and BAT as a compensatory mechanism to the genetic deletion (Lu et al., 2015). 
Moreover, glucocorticoids have been shown to down-regulate Crhr2 in the ventromedial 
nucleus of hypothalamus (VMH) and not in the paraventricular nucleus (PVN), thus 
controlling appetite and other eating disorders (Chen et al., 2005), therefore this could 
also justify how low levels of corticosterone in Crh KO mice (Muglia et al., 1995) could 
have diminished their inhibitory effects on expression of Crhr2 in this genotype. Since, 
it was reported that glucocorticoid replacement could reverse the effect of Crhr1 
deletion on Crhr2 expression (Lu et al., 2015), it remains to be elucidated whether 
corticosterone supplementation in Crh KO mice also reversed the observed effect in 
BAT and other tissues. The lack of WT responsiveness, measured by phospho-Akt/total 
Akt ratio, suggested either that the CRHR2 ligands could not activate Akt or that Akt 
could not be activated, probably due to impairment in upstream signalling molecules. 
The former scenario could have resulted from various causes: the receptor could be 
internalized and thus was not able to bind CRH/UCN2 and activate the signalling 
cascade; a delayed response could be generated as this was also reported for a different 
cellular model (THP1 monocytic cells), where CRH and UCN2 significantly increased 
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phospho-Akt/total Akt ratio after 30 minutes of stimulation (Chandras et al., 2009); 
lastly, it could be possible that WT CRHR2 levels were minimal and ligands were 
ineffective. Therefore, further studies are needed in order to address some of the 
hypotheses discussed above, such as perform time- and dose-dependent experiments and 
determine CRHR2 cellular localization with immunostaining before and after 
glucocorticoid replacement. The latter scenario that could perhaps explain the lack of 
WT responsiveness (measured by phospho-Akt/total Akt ratio) to CRH and UCN2 could 
implicate impairment in the regulators of G protein signalling (RGS). These molecules 
accelerate GTP hydrolysis catalyzed by Gα G protein subunits upon binding to GPCRs, 
thus terminating the GPCR signal. It has been shown that various members of the RGS 
family are involved in enhancing lipolysis (Iankova et al., 2008), in regulating body 
weight (Waugh et al., 2011) and in promoting obesity and insulin resistance (Deng et al., 
2012). Therefore, RGSs could be differentially expressed in WT and Crh KO adipose 
tissue. The latter along with their reported regulation from glucocorticoids (Holden et 
al., 2011; Holden et al., 2014; Ni et al., 1999) could further enhance these differences 
and hence resulting in modulation of the CRHR2 signalling. 
The characteristic glucocorticoid insufficient environment of Crh KO mice 
could not have directly affected basal phospho-Akt/total Akt ratio in brown adipocytes 
since the result shown in Figures 4.1-1 and 4.1-2 was opposite to what has already been 
published and described above, meaning that the reduced corticosterone in Crh KO mice 
was expected to increase basal phospho-Akt/total Akt ratio. Therefore, it should be 
noted that glucocorticoids could affect other mediators of CRHR2 signalling pathway, 
such as the RGS as described previously. In the control condition (=no CRH/UCN2 
stimulation), the lower levels of phospho-Akt/total Akt ratio in Crh KO adipocytes 
compared to WT indicate that the activation mechanism of Akt in Crh KO cells was 
impaired. However, the significant increase of phospho-Akt/total Akt ratio after CRH 
and UCN2 treatments indicated that Crh KO adipocytes are more sensitive to these 
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stimuli compared to WT, perhaps due to increased levels of Crhr2 (Karaliota et al., 
unpublished data). Total Akt levels were not affected by glucocorticoid treatment in 
previous studies, suggesting that the elevated Crh KO total Akt levels compared to WT 
levels (Figure 4.1-1C) did not result from low corticosterone levels. Instead, it could be a 
developmental effect as discussed previously or Crh KO brown adipocytes were more 
insulin sensitive thus resulting in increased Akt levels. Additionally, analysis of whole 
brown adipose tissues from WT and Crh KO mice showed that phospho-Akt/total Akt 
ratio and total Akt (Figure 4.2) were unchanged between the genotypes. This suggested 
that the tissue and the isolated, cultured and differentiated preadipocytes had totally 
different signalling characteristics. Furthermore, this indicated that Crh KO brown 
adipocytes could activate Akt protein synthesis only upon stimulation, for example after 
the addition of differentiation agents, such as insulin, in the culture media. 
The inhibitory actions of SU6656 on phospho-Akt/total Akt ratio were 
previously reported in pancreatic cancer cells (Asano et al., 2005), in endothelial cells 
(Cuneo et al., 2006) and in melanoma cells (Ondrusova et al., 2013), where it suppressed 
tumour growth in time periods as early as 30 minutes and 2 hours. My results are in 
agreement with these reports. Particularly, phospho-Akt/total Akt ratio was significantly 
inhibited after SU6656 treatment and the 5-minute CRH and UCN2 stimulations (Figure 
4.1-2D). Despite the lack of the proper control condition with only SU6656 treatment, 
due to very low protein concentration of those samples, the fact that CRH and UCN2 did 
not have an effect on WT phospho-Akt/total Akt ratio suggested that Fyn was directly 
associated with Akt and thus inhibition of Fyn resulted in reduction of phospho-Akt/total 
Akt ratio. The latter association was supported by the reported interaction of Fyn and 
IRS1 (Myers et al., 1996; Sun et al., 1996), linking Fyn and Akt in the insulin signalling 
pathway. Significant inhibition of phospho-Akt/total Akt ratio was also reported for the 
15-minute UCN2 treatment (Figure 4.1-2E), indicating that this process was also Fyn-
dependent. However, no change was measured for the 15-minute CRH treatment, 
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indicating that SU6656 exerted its effects on the most potent CRHR2 ligand, UCN2, 
explaining also the reason for detecting these effects at the 15-minute time-point, 
pointing to the necessity for Fyn being intact at different time-points. Transient effects 
on phospho-Akt/total Akt ratio, similar to the ones reported here after SU6656 and CRH 
stimulations, have also been studied. Reports, which performed time course 
experiments, provided evidence of mechanisms that transiently inhibited 
phosphorylation of Akt and included the Parkinson‟s disease mimetic drug, 6-
hydroxydopamine (Chen et al., 2004b) or inhibitors of the catalytic subunit, p110, of 
PI3K (Torbett et al., 2008). 
Summarizing my results on Akt in primary brown adipocytes, it was shown that 
CRH and mainly UCN2 activated CRHR2 and in turn, CRHR2 activated Akt in Crh KO 
adipocytes. On the other hand, CRH and UCN2 stimuli failed to produce any response in 
WT cells. The fact that Akt was activated only in Crh KO adipocytes could have a 
significant biological role since Akt is an important downstream mediator of the insulin 
signalling pathway. Therefore, Crh KO brown adipocytes could have an increased 
insulin-insulin receptor-IRS1-PI3K-Akt pathway and thus have increased glucose uptake 
resulting from the increased insulin sensitivity reported from ITT experiments in Crh 
KO mice (Karaliota et al., unpublished data). In case this hypothesis will be validated, 
then it would be opposite to the reported inhibitory actions of CRHR2 in skeletal muscle 
on insulin sensitivity (Chen et al., 2006; Kuperman and Chen, 2008), thus establishing 
tissue-specificity for CRHR2 on regulating glucose uptake. Further, an additional 
biological role could be discussed as Akt is negatively regulating lipolysis and this will 
be analyzed below. Inhibition of Fyn kinase activity by SU6656 provided evidence that 
Fyn was associated with Akt and there were no interactions with CRHR2. 
The ERK1/2 signalling pathway has been extensively studied downstream of 
CRHR2. All peptides of CRH family have been shown to bind to CRHR2 and stimulate 
ERK1/2, although the latter was activated to a lesser extend after CRH compared to 
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UCNs (Wu et al., 2007). The latter could support my results where phospho-
ERK1/2/total ERK1/2 ratio was almost unchanged in WT adipocytes (Figure 4.3-1A). 
However, as discussed for Akt, it is likely that the magnitude of WT ERK1/2 activation 
might be regulated by the level of CRHR2 expression, signal transduction potential and 
affinity, independently or combined. Contrary to CRH, UCNs bind to CRHR2 with 
higher affinity (Bale and Vale, 2004) and activate ERK1/2 very quickly, for example 
within 5 minutes after addition in vitro (Huang et al., 2009; Kageyama et al., 2010; Wu 
et al., 2007). The role of this pathway has been studied in a plethora of experimental 
settings: delayed effects of stress on memory formation were mediated by CRHR2-
ERK1/2 induction (Sananbenesi et al., 2003); control of human pregnant myometrial 
cells was displayed by this pathway (Karteris et al., 2004); cardioprotective effects after 
ischemic reperfusion injury in rat hearts (Schulman et al., 2002) and isolated 
cardiomyocytes (Brar et al., 2004b) were generated by activation of UCNs-CRHR2-
ERK1/2 cascade; pro-inflammatory effects of this pathway regulated the 
pathophysiology of colitis in humans (Moss et al., 2007); prevention of cancer 
progression was mediated by UCNs-CRHR2-ERK1/2 pathway (Ducarouge et al., 2013; 
Kageyama et al., 2010); and this cascade also regulated β-arrestin 1, therefore 
controlling CRHR2 internalization (Markovic et al., 2011). My results confirmed that 
UCN2 activated CRHR2-ERK1/2 in brown adipocytes with a rapid response for Crh KO 
cells and lower for WT (Figure 4.3-1B). 
The involvement of glucocorticoids in regulation of phospho-ERK1/2 levels 
presented controversial results, which varied in different experimental settings. More 
specifically, dexamethasone inhibited ERK1/2 in lung cancer cells to prevent tumour 
growth (Greenberg et al., 2002); in colon cancer cells to prevent migration (Han et al., 
2015); and dexamethasone and cortisol decreased phospho-ERK1/2 during oocyte 
maturation in lamb (Gonzalez et al., 2010). The enhancing effects of glucocorticoids on 
ERK1/2 were reported in PC12 neural cells (Qiu et al., 2001), in survival of renal cells 
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after ischemia reperfusion injury (Kumar et al., 2009) and in ovarian follicular cells 
where it exerted an anti-apoptotic role (Sasson et al., 2003). Hence, glucocorticoids did 
not have a similar pattern of action on activation of ERK1/2. Overall, this evidence 
makes it impossible to ascertain whether Crh KO glucocorticoid insufficiency (Muglia 
et al., 1995) was implicated in the regulation of ERK1/2 levels, both the phosphorylated 
form (Figures 4.3-1 and 4.3-2) and the total (Figure 4.3-1C), measured in this study 
under basal conditions. 
A small number of studies investigated the role of SU6656 on ERK1/2 
activation, but all concluded that this inhibitor reduced phospho-ERK1/2/total ERK1/2 
ratio after 24 hours (Cicha et al., 2014; Garcia-Martin et al., 2013; Taniguchi et al., 
2013; Tian et al., 2009). In this experiment, SU6656 did not alter phospho-ERK1/2/total 
ERK1/2 ratio (Figure 4.3-2D and E), although the 2-hour treatment was shown to inhibit 
Fyn kinase activity (Bastie et al., 2007) and my studies also showed effects on 
phosphorylation of Akt (Figure 4.1-2D and E). Thus, it seems likely that Fyn was not 
involved in CRHR2-mediated activation of ERK1/2. The reduction in phospho-
ERK1/2/total ERK1/2 ratio observed in the 5-minute UCN2-treated Crh KO cells 
(Figure 4.3-2D), could either have no biological significance or an inhibitory role was 
unraveled for CRHR2. 
In conclusion, CRH activated ERK1/2 to a smaller extent and this response was 
delayed compared to UCN2 in Crh KO cells. The natural ligand of CRHR2, UCN2, 
activated ERK1/2 in WT adipocytes as well, a result supported by previous studies. The 
biological significance of these increases in phospho-ERK1/2/total ERK1/2 ratio could 
link CRHR2 to adipocyte differentiation since it was shown that both isoforms, ERK1 
and ERK2, were necessary for maturation of preadipocytes and proliferation (Bost et al., 
2005; Bost et al., 2002; Donzelli et al., 2011; Prusty et al., 2002; Sale et al., 1995). 
Moreover, CRHR2 was shown to promote brown adipocyte differentiation (Lu et al., 
2015), thus further strengthening the above notion. Additional supporting information 
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that ERK1/2 displayed an important role in adipocyte differentiation was provided by 
the inability to detect phospho-ERK1/2 in whole brown adipose tissue lysates, which 
consisted mainly from mature adipocytes (immunoblots not shown), suggesting that 
under basal conditions ERK1/2 was not activated. Total ERK1/2 levels were unchanged 
between WT and Crh KO BAT, as evident from Figure 4.4. Inhibition of Fyn activity 
did not reverse the effects of CRH and UCN2 on phospho-ERK1/2/total ERK1/2 ratio, 
concluding that Fyn was not interacting with ERK1/2. 
 
When isolating and culturing primary preadipocytes, it is important to note that 
although they provide a useful tool in experimental design, the results obtained from 
such cultures should be treated with caution. The advantages of using primary 
preadipocytes are that they partially mimic the functions of the adipose tissue and they 
consist of a cell-autonomous system. 
As previously shown (chapter 3), Crh KO white and brown adipose tissues had 
an attenuated response to isoproterenol-induced lipolysis compared to WT (Figure 3.11). 
This could be explained by the increased fatty acid oxidation of Crh KO white adipose 
tissues (Karaliota et al., unpublished data) and/or by reduced expression of β3-AR 
compared to WT. The greater effect of isoproterenol on phosphorylation of HSL was 
reported for the subcutaneous adipose tissue, followed by epididymal and brown adipose 
tissues (Figure 3.11). As discussed in chapter 3, this could be supported by the metabolic 
phenotype of Crh KO mice (Karaliota et al., unpublished data). In particular, the 
increased numbers of beige cells in Crh KO subcutaneous depots could potentially 
express more β3-ARs, therefore making the subcutaneous depots more sensitive to 
isoproterenol-induced lipolysis. Epididymal fat pad, which did not contain beige cells 
(Karaliota et al., unpublished data), showed less sensitivity to isoproterenol-induced 
lipolysis in terms of phospho-HSL, compared to the subcutaneous fat, whereas BAT was 
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the least sensitive of all adipose tissues, as probably more time was needed to stimulate 
this tissue (detailed discussion in chapter 3). 
My in vitro data showed that the lipolytic effect of isoproterenol, measured by 
phosphorylation of HSL Ser563, was more prominent in the epididymal and brown 
adipocytes followed by the subcutaneous cells (Figure 4.5A, B and C). This was in 
agreement to the reported increased lipolytic capacity of epididymal adipose tissue due 
to increased β3-AR compared to subcutaneous fat (Arner, 1995), thus serving as a 
primary energy pool. The highly expressed β3-AR in BAT compared to WAT (Muzzin 
et al., 1991; Wajchenberg, 2000), explained why brown adipocytes were more sensitive 
to isoproterenol compared to subcutaneous, whereas brown adipocytes could not display 
responses greater to epididymal adipocytes perhaps due to differences in expression of 
other β-ARs, like β1-AR and/or β2-AR. This also showed that BAT was able to respond 
to the isoproterenol-induced lipolysis in my in vivo experiment, but the time-point used 
was not sufficient to generate such stimulation, as discussed in chapter 3. These data 
provided evidence that cultures of preadipocytes produced different results from the 
systemic response that was measured upon isoproterenol injection in mice. In 
conclusion, the effect observed by examining whole adipose tissues was not cell-
autonomous, rather it resulted from the genetic deletion of Crh and the ensuing 
metabolic phenotype. 
In the adipocyte cultures, Crh KO cells exhibited greater responses to 
isoproterenol than WT cells (Figure 4.5A, B and C). But this was only evident in the 
white and not the brown adipose-deriving cells, indicating that only Crh KO white fat 
had higher levels of β-ARs than WT and not brown, and this was perhaps a result of the 
different origin of these specific fat pads (Kajimura et al., 2015). This hypothesis 
remains to be elucidated by measuring the expression profile of β-ARs in WT and Crh 
KO adipose tissues. Additionally, the increased expression of Akt in Crh KO brown 
adipocytes compared to WT (Figure 4.1-1C) could also attenuate lipolysis as reported 
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elsewhere (Jaworski et al., 2007; Wijkander et al., 1998). As a consequence, the 
adipocyte cultures unmasked a unique effect of global Crh deficiency and of its 
characteristic reduced circulating corticosterone on regulation of lipolysis processes in 
adipose tissues. 
Fyn KO mice owe their lean phenotype, partly, to the increased fatty acid 
oxidation in skeletal muscle and adipose tissue (Bastie et al., 2007). However, the 
lipolytic pathway has not been examined yet and it could also be altered, therefore 
linking Fyn and hydrolysis of lipids. As a consequence, SU6656 could either increase or 
decrease the lipolytic processes in this cellular setting. The increase was reported for the 
WT epididymal adipocytes (Figure 4.5E) and this could be justified by reduced Akt 
levels in WT epididymal adipocytes compared to Crh KO, similarly to brown adipocytes 
(Figure 4.1-1C). Contrary to that, SU6656 decreased phospho-HSL in WT subcutaneous 
adipocytes (Figure 4.5D), which remains to be further examined as total expression of 
HSL needs to be determined and also measure Akt levels, which indirectly regulate 
lipolytic processes (Jaworski et al., 2007; Wijkander et al., 1998). Similarly to the in 
vivo data (Figure 3.12), Fyn protein expression was not altered upon isoproterenol and 
SU6656 stimulations (Figure 4.6). Particularly, it has not been shown that inhibition of 
Fyn activity reduces Fyn expression and the 15-minute treatment with isoproterenol 
either did not alter Fyn protein expression due to the small incubation time or Fyn did 
not regulate phosphorylation of HSL. 
In summary, in primary differentiated brown adipocytes I examined part of the 
CRHR2 signalling characteristics and concluded that Fyn was interacting with Akt 
independently of CRHR2 and that Fyn was not involved in CRHR2-mediated activation 
of ERK1/2. Further, the combination of the in vivo and in vitro data upon stimulation of 
lipolysis processes provided evidence that the in vivo effects were not cell-autonomous 
and resulted from the metabolic phenotype developed due to deletion of Crh. More 
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studies are needed in order to fully elucidate the lipolytic capacities and CRHR 
signalling cascades of adipose tissues. 
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Chapter 5 
Summary and conclusion 
 The understanding of the molecular mechanisms that underlie whole-body 
energy homeostasis is essential as dysregulations cause a large number of diseases, 
including obesity and cardiovascular diseases that are often associated with increased 
mortality risk. In this study, I focused on investigating CRH and Fyn kinase, two 
molecules that are implicated in metabolism and are regulated by the HPA axis. CRH 
has been examined for the anorexigenic effects upon its exogenous administration in 
rodents (Arase et al., 1988; Krahn et al., 1990; Morley and Levine, 1982). Furthermore, 
the induction of the sympathetic nervous system and subsequent increases in 
thermogenesis, norepinephrine and glucocorticoid release (Cullen et al., 2001) clearly 
indicated CRH as a mediator of energy availability. All members of the CRH family of 
peptides have been shown, either by genetic deletions (Bale et al., 2003; Chen et al., 
2006; Li et al., 2007; Zalutskaya et al., 2007) or overexpression (Jamieson et al., 2011) 
and in vivo injections (Cullen et al., 2001; Seres et al., 2004), to be potent mediators of 
metabolic processes. The recent finding that CRH/CRHR1 or UCN2/CRHR2 regulate 
adipose tissue differentiation to white or beige, respectively, suggested that CRH family 
of peptides could participate in adipogenesis (Lu et al., 2015).  Interestingly, the analysis 
of the Crh KO mice metabolic phenotype (Karaliota et al., unpublished data), revealed 
increased lipid utilization with increased fatty acid oxidation in white adipose tissues. 
Additionally, the Crh KO mice also displayed an expanded and functional beige 
compartment in the subcutaneous adipose tissue, which might explain the increased 
thermogenesis also observed in these mice. These studies strengthened the role of CRH 
in regulation of energy homeostasis. Finally, a large body of evidence implicates CRH in 
the development of anxiety-related disorders (Bale and Vale, 2004). Interestingly, 
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however, Crh KO mice display normal anxiety under stressful conditions (Dunn and 
Swiergiel, 1999; Weninger et al., 1999a), due to compensatory mechanisms, such as 
urocortins. 
Fyn kinase, on the other hand, was reported to play significant role in white 
adipogenesis (Sun et al., 2005; Tse et al., 2013) and the Fyn KO mice displayed a 
remarkable phenotype characterized by reduced body weight and reduced adiposity in 
white fat pads accompanied by increased fatty acid oxidation in skeletal muscle and 
white adipose tissues (Bastie et al., 2007). Lastly, Fyn kinase was shown to be regulated 
by the HPA axis, suggested by the fact that Fyn KO mice displayed increased anxiety 
(Belzung and Griebel, 2001; Miyakawa et al., 1994) and Fyn kinase expression was 
down-regulated by glucocorticoids (Harr et al., 2010). 
 My experiments resulted in the discovery of a novel regulation of Fyn kinase by 
CRH, either directly or indirectly. This positive effect of CRH on Fyn kinase expression, 
in all the tissues that were examined, was unmasked when Crh KO mice were 
supplemented with corticosterone (Figures 3.2-1 and 3.2-2), the main glucocorticoid in 
mice, in order to correct the glucocorticoid insufficiency and HPA axis output resulting 
from the global Crh deficiency (Muglia et al., 1995). Activation of catabolic processes 
through cold exposure decreased Fyn expression levels in all tissues examined (Figures 
3.2-1 and 3.2-2), suggesting that mobilization of energy reserves affected Fyn. This is 
particularly in line with the role of Fyn kinase as a regulator of lipid utilization (Bastie et 
al., 2007), since a reduction of Fyn kinase expression or activity was reported to increase 
β-oxidation in adipose tissues (and muscle), an event that is undeniably also apparent 
under cold challenge. Furthermore, low temperatures increased circulating 
corticosterone (Harper and Austad, 2000; Karp, 2012), which in turn enhanced catabolic 
processes and further reduced Fyn kinase expression (Harr et al., 2010), therefore 
affecting β-oxidation pathway. Consequently, examination of the effects of 
glucocorticoid replacement using indirect calorimetry could be done in the future to 
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determine whether elevation of blood corticosterone affects energy expenditure, activity 
and food intake. Since it was shown that alterations in expression of CRH family of 
peptides occur due to genetic deletions and reversed upon corticosterone delivery (Lu et 
al., 2015), it is likely that compensatory mechanisms also arose in the Crh KO mouse. 
Therefore, it remains to be elucidated whether urocortins expression was altered and 
whether this was secondary to the glucocorticoid insufficiency. Significant information 
could also be collected from the inhibition of Fyn kinase activity using the SU6656 
inhibitor in the Crh KO mice (Yamada et al., 2010). Indirect calorimetry, mRNA and 
protein expression levels, after just one SU6656 injection, would help elucidate whether 
inhibiting Fyn kinase activity in the Crh KO mice would result in an even greater lipid 
oxidation profile than the Crh KO mouse. If that was observed, this would suggest a 
synergistic action of CRH and Fyn kinase. In order to confirm these results, the use of a 
proper double knockout (with Fyn kinase totally deleted or using tissue-specific 
deletion) will be necessary. 
 Stimuli that activate brown adipose tissue have been the basis of experimental 
studies since brown adipose tissue and the beige compartment generated in white 
adipose tissues have been reported to exert beneficial effects on obesity, insulin 
sensitivity and glucose clearance (Kajimura et al., 2015). Despite the efforts to produce 
drugs that stimulate brown adipose tissue thermogenesis, the adverse effects on the 
cardiovascular system have put a barrier to this research. One such example of drug with 
adverse effects is the β-adrenergic agonists which have been used because this pathway 
plays a key role in activation of brown adipose tissue thermogenesis (Villarroya and 
Vidal-Puig, 2013). In this study, glucocorticoid replacement and cold exposure were 
used as potent stimulators of brown adipose tissue thermogenesis (Gasparetti et al., 
2003; Lim et al., 2012; Soumano et al., 2000; Viengchareun et al., 2001), thus I sought 
to determine the role of Fyn kinase in brown adipogenesis. Use of the brown 
preadipocyte cell line, T37i, enabled the description of a novel role for Fyn, since 
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inhibition of Fyn kinase activity attenuated adipocyte differentiation, indicating a 
significant role in promoting maturation and full functionality of brown adipocytes 
(section 3.3). Although the effects on adipocyte differentiation due to lack of Crh were 
not determined, we could speculate that CRH could play an important role in promoting 
adipogenesis, similarly to Fyn kinase, a concept that was also supported by unpublished 
data (Karaliota et al.). 
 Lipolysis processes, which partly control the availability of lipids as substrates 
for tissues capable of β-oxidation (adipose tissues and muscles), have also been studied 
in this project, in terms of recording differences between WT and Crh KO mice and 
determining the involvement of Fyn kinase. Although isoproterenol, a potent stimulator 
of lipolysis, is known to exert its actions primarily in epididymal fat depots (Lacasa et 
al., 1991), the Crh KO mice generated differential results (Figure 3.11). Importantly, the 
expanded beige compartment in the subcutaneous adipose tissue (Karaliota et al., 
unpublished data) increased the response of this depot to isoproterenol-induced lipolysis, 
thus epididymal fat was less prone to the lipolytic effects of isoproterenol. On the 
contrary, this susceptibility of epididymal adipocytes to lipolysis was evident in primary 
cultures of preadipocytes isolated from WT and Crh KO mice (Figure 4.5), indicating 
that the in vivo effect of isoproterenol was, very likely counter balanced by additional 
signals (which still remain to be determined) and thus, it was not cell-autonomous. 
Furthermore, isoproterenol is reported to activate lipolysis in brown adipose tissue along 
with thermogenesis, which is evident by increased Ucp1 expression (Cannon and 
Nedergaard, 2004). The duration of my in vivo experiments limited the actions of 
isoproterenol in white adipose tissues (Figure 3.11) but the brown adipocytes were 
responsive in the cellular cultures (Figure 4.5), thus establishing that lipolysis in brown 
adipose tissue was not impaired in Crh KO mice. The absence of effect in vivo again 
suggested that additional mechanisms might diminish the effects of β-adrenergic 
stimulation of lipolysis. Moreover, the unchanged levels of Fyn kinase upon 
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isoproterenol injection (Figure 3.12) provided evidence that either hydrolysis of lipids 
was independent of Fyn kinase or that the incubation was too short to affect (if at all) 
Fyn protein levels. Both of these events should be addressed in future experiments and 
Fyn-mediated lipolysis should be examined. 
 The traditional role of CRH in the hypothalamus-pituitary-adrenal (HPA) axis to 
control autonomic, behavioural, immune and cognitive responses to stress, as well as its 
peripheral functions, such as on metabolism, energy homeostasis, gastrointestinal and 
immune systems, have been mediated via activation of the CRH receptors (CRHRs). 
The signalling cascades, following ligand binding to CRHRs, have been extensively 
reviewed (Grammatopoulos, 2012). In my primary brown adipocytes experiment, some 
of the CRHR2 signalling molecules were investigated, particularly Akt (Figures 4.1-1, 
4.1-2 and 4.2) and ERK1/2 (Figures 4.3-1, 4.3-2 and 4.4). Both molecules are implicated 
in controlling adipocyte development and differentiation (Bost et al., 2005; Bost et al., 
2002; Donzelli et al., 2011; Garofalo et al., 2003; Gonzalez and McGraw, 2009; 
Hernandez et al., 2001; Prusty et al., 2002; Sale et al., 1995). In addition to the 
differences reported between WT and Crh KO adipocytes after CRH and UCN2 
stimulations, the effects of Fyn kinase activity inhibition were examined, using the 
specific inhibitor SU6656. Importantly, the differences between WT and Crh KO 
adipocytes require further investigation in order to elucidate the exact role of Crh 
deficiency and of the ensuing low circulating corticosterone, since the differences were 
measured in the basal state. Whether developmental cues controlled these events or 
differential energy needs drive different phosphorylation events, is still unknown. In 
parallel, and as mentioned previously, compensatory mechanisms due to genetic 
deletions, such as increased CRHR2 (Lu et al., 2015) in Crh KO brown adipose tissue, 
could be the basis of the phenotypes reported in this study. 
The effects of SU6656 on CRHR2 signalling characteristics concluded that 
although Fyn was associated with Akt, this was not the case with CRHR2 and ERK1/2. 
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The former characteristic provided another linking point between Fyn, Akt and insulin 
signalling, complementing previous studies (Liu et al., 2005; Saltiel and Pessin, 2003). 
In addition to the roles of CRHR2 (Lu et al., 2015) and ERK1/2 (Bost et al., 2005; Bost 
et al., 2002; Donzelli et al., 2011; Prusty et al., 2002; Sale et al., 1995) in mediating 
adipocyte differentiation, my results strengthened this notion since CRH and UCN2 
increased phospho-ERK1/2/total ERK1/2 ratio in WT and Crh KO brown adipocytes 
(Figures 4.3-1 and 4.3-2). 
 
Results of this thesis provide evidence of a novel positive correlation between 
CRH and Fyn kinase, which not only strengthens their role in regulating energy balance 
but also could be used as potential therapeutic targets to treat obesity and/or other 
metabolic disorders. The latter was evident from animals with genetic deletions of Crh 
or Fyn kinase, which display a lean phenotype with beneficial effects in whole-body 
insulin sensitivity, even under caloric excess (high-fat diet). The important role of Fyn 
kinase in promoting brown adipogenesis complements its fundamental role in 
controlling white adipogenesis. The former along with the anti-obesity effects of brown 
adipose tissue could consist of another plausible approach to increase brown adipose 
tissue activity and therefore whole-body energy expenditure. 
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